TERT promoter mutations occur frequently in gl derived from cells with low rates of self-renewal

Proceedings of the National Academy of Sciences of the Unite

110, 6021-6026

DOI: 10.1073/pnas.1303607110

Citation Report

#	Article	IF	Citations
1	Protein Residues That Control the Reaction Trajectory in S-Adenosylmethionine Radical Enzymes: Mutagenesis of Asparagine 153 and Aspartate 155 in Escherichia coli Biotin Synthase. Biochemistry, 2009, 48, 2448-2458.	1.2	21
2	LOW GRADE GLIOMAS. Neuro-Oncology, 2012, 14, i69-i81.	0.6	5
3	TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. British Journal of Cancer, 2013, 109, 497-501.	2.9	103
4	Frequency of TERT promoter mutations in human cancers. Nature Communications, 2013, 4, 2185.	5.8	740
5	The chromatin remodeller ATRX: a repeat offender in human disease. Trends in Biochemical Sciences, 2013, 38, 461-466.	3.7	103
6	TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathologica, 2013, 126, 931-937.	3.9	209
7	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451.	3.9	304
8	Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics. Science, 2013, 342, 1235587.	6.0	341
9	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature Communications, 2013, 4, 2218.	5.8	513
10	Inhibition of Telomerase Recruitment and Cancer Cell Death. Journal of Biological Chemistry, 2013, 288, 33171-33180.	1.6	42
11	A Nondegenerate Code of Deleterious Variants in Mendelian Loci Contributes to Complex Disease Risk. Cell, 2013, 155, 70-80.	13.5	209
12	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	3.9	254
13	TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathologica, 2013, 126, 939-941.	3.9	62
14	TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Research, 2013, 73, 7162-7167.	0.4	214
15	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
16	Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathologica, 2013, 126, 789-792.	3.9	15
17	Telomere length and risk of glioma. Cancer Epidemiology, 2013, 37, 935-938.	0.8	28
18	Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes and Development, 2013, 27, 2513-2530.	2.7	220

#	Article	IF	Citations
19	Integration of cancer genomics with treatment selection. Cancer, 2013, 119, 3914-3928.	2.0	15
20	Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathologica, 2013, 126, 267-276.	3.9	315
21	Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Genome Medicine, 2013, 5, 66.	3.6	23
22	Highly prevalentTERTpromoter mutations in bladder cancer and glioblastoma. Cell Cycle, 2013, 12, 1637-1638.	1.3	123
23	Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1562-E1566.	1.8	378
24	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	3.9	146
25	Cellâ€“cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas. Nature Communications, 2013, 4, 2531.	5.8	71
26	Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Critical Reviews in Biochemistry and Molecular Biology, 2013, 48, 522-543.	2.3	113
27	The molecular landscape of diffuse glioma and prospects for biomarker development. Expert Opinion on Medical Diagnostics, 2013, 7, 573-587.	1.6	9
28	Molecular insights into brain tumors. Current Opinion in Neurology, 2013, 26, 678-680.	1.8	1
29	Next-generation molecular genetics of brain tumours. Current Opinion in Neurology, 2013, 26, 681-687.	1.8	15
30	Predictive biomarkers in adult gliomas. Current Opinion in Oncology, 2013, 25, 689-694.	1.1	34
31	Genetics in glioma. Current Opinion in Neurology, 2013, 26, 688-692.	1.8	21
32	TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17426-17431.	3.3	291
33	Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a014415-a014415.	2.9	480
34	Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes and Cancer, 2013, 52, 873-886.	1.5	238
35	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer, 2013, 20, 603-610.	1.6	500
36	In search of molecular markers of glioma in elderly patients. Nature Reviews Neurology, 2013, 9, 424-425.	4.9	9

#	Article	IF	Citations
37	Clonal Architectures and Driver Mutations in Metastatic Melanomas. PLoS ONE, 2014, 9, e111153.	1.1	69
38	Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells. PLoS ONE, 2014, 9, e112438.	1.1	28
39	An Improved Model for the hTERT Promoter Quadruplex. PLoS ONE, 2014, 9, e115580.	1.1	55
40	Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia. BioMed Research International, 2014, 2014, 1-5.	0.9	26
41	Telomere Maintenance Mechanisms in Cancer: Clinical Implications. Current Pharmaceutical Design, 2014, 20, 6361-6374.	0.9	74
42	Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment. Frontiers in Oncology, 2014, 4, 47.	1.3	36
43	Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Review of Molecular Diagnostics, 2014, 14, 439-452.	1.5	69
44	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opinion on Pharmacotherapy, 2014, 15, 2047-2061.	0.9	19
45	In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cellular and Molecular Life Sciences, 2014, 71, 4007-4026.	2.4	42
46	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathologica, 2014, 128, 853-862.	3.9	46
47	OncoCis: annotation of cis-regulatory mutations in cancer. Genome Biology, 2014, 15, 485.	3.8	22
48	FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. Genome Biology, 2014, 15, 480.	3.8	291
49	The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia, 2014, 28, 1371-1374.	3.3	85
50	Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 673-677.	1.4	52
51	Is the volume of low-grade glioma measurable and is it clinically relevant?. Neuro-Oncology, 2014, 16, 1027-1028.	0.6	4
52	Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas". Neuro-Oncology, 2014, 16, 891-892.	0.6	0
53	Mathematical Model of a Telomerase Transcriptional Regulatory Network Developed by Cell-Based Screening: Analysis of Inhibitor Effects and Telomerase Expression Mechanisms. PLoS Computational Biology, 2014, 10, e1003448.	1.5	13
54	Genetic Basis of Thrombosis in Cancer. Seminars in Thrombosis and Hemostasis, 2014, 40, 284-295.	1.5	19

#	Article	IF	Citations
55	EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing. Cancer Discovery, 2014, 4, 956-971.	7.7	251
56	Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurgical Focus, 2014, 37, E11.	1.0	147
57	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	0.6	77
58	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes and Cancer, 2014, 53, 15-24.	1.5	91
59	Absence of TERT promoter mutations in esophageal adenocarcinoma. International Journal of Cancer, 2014, 134, 2014-2015.	2.3	5
60	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
61	<scp>TERT</scp> promoter mutation is uncommon in acral lentiginous melanoma. Journal of Cutaneous Pathology, 2014, 41, 504-508.	0.7	37
62	Recurrent TERT promoter mutations in non-small cell lung cancers. Lung Cancer, 2014, 86, 369-373.	0.9	27
63	Proteostatic Control of Telomerase Function through TRiC-Mediated Folding of TCAB1. Cell, 2014, 159, 1389-1403.	13.5	126
64	TERT promoter mutations predict worse survival in laryngeal cancer patients. International Journal of Cancer, 2014, 135, 1008-1010.	2.3	40
65	Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers. International Journal of Cancer, 2014, 134, 2993-2994.	2.3	30
66	TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer, 2014, 120, 2965-2979.	2.0	93
67	Absence of <scp>TERT</scp> promoter mutations in primary melanocytic tumours of the central nervous system. Neuropathology and Applied Neurobiology, 2014, 40, 794-797.	1.8	19
68	International progress: from cytology to genomics. Nature Reviews Urology, 2014, 11, 609-610.	1.9	6
69	High Incidence of Activating <scp>TERT</scp> Promoter Mutations in Meningiomas Undergoing Malignant Progression. Brain Pathology, 2014, 24, 184-189.	2.1	209
70	A global assessment of cancer genomic alterations in epigenetic mechanisms. Epigenetics and Chromatin, 2014, 7, 29.	1.8	64
71	Molecular Genetics of Gliomas. Cancer Journal (Sudbury, Mass), 2014, 20, 66-72.	1.0	93
72	Alterations of theRRASandERCC1Genes at 19q13 in Gemistocytic Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2014, 73, 908-915.	0.9	7

#	Article	IF	Citations
73	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology, 2014, 16, 81-91.	0.6	370
74	The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocrine-Related Cancer, 2014, 21, 427-434.	1.6	65
75	Emerging Therapies for Glioblastoma. JAMA Neurology, 2014, 71, 1437.	4.5	148
76	Cell Senescence in Myxoid/Round Cell Liposarcoma. Sarcoma, 2014, 2014, 1-7.	0.7	11
77	Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine. European Urology, 2014, 65, 367-369.	0.9	137
78	Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Modern Pathology, 2014, 27, 516-523.	2.9	92
79	TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Modern Pathology, 2014, 27, 502-508.	2.9	108
80	TERT promoter mutations in cancer development. Current Opinion in Genetics and Development, 2014, 24, 30-37.	1.5	203
81	Exploring the association between melanoma and glioma risks. Annals of Epidemiology, 2014, 24, 469-474.	0.9	23
82	Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics. Neuroscience, 2014, 264, 171-185.	1.1	45
83	Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. International Journal of Cancer, 2014, 134, 493-494.	2.3	23
84	Brain and Spinal Cord. , 2014, , 1384-1426.		0
85	Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene, 2014, 33, 3748-3752.	2.6	68
86	Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome. European Urology, 2014, 65, 360-366.	0.9	215
87	Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. Neuro-Oncology, 2014, 16, 400-408.	0.6	13
88	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. Journal of Pathology, 2014, 232, 473-481.	2.1	81
89	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. Cancer Cell, 2014, 25, 428-441.	7.7	240
90	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627

#	Article	IF	Citations
91	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. Clinical Cancer Research, 2014, 20, 2898-2909.	3.2	146
92	The epidemiology of glioma in adults: a "state of the science" review. Neuro-Oncology, 2014, 16, 896-913.	0.6	1,586
93	TERTPromoter Mutations and Their Association withBRAFV600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1130-E1136.	1.8	262
94	Pathology of Gliomas and Developments in Molecular Testing. Clinical Oncology, 2014, 26, 377-384.	0.6	5
95	The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene, 2014, 33, 4978-4984.	2.6	215
96	Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology, 2014, 386, 101-120.	1.6	32
97	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469
98	Genomic Sequencing for Cancer Diagnosis and Therapy. Annual Review of Medicine, 2014, 65, 33-48.	5.0	35
99	TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. Acta Neuropathologica, 2014, 127, 307-309.	3.9	49
100	Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nature Genetics, 2014, 46, 1267-1273.	9.4	655
101	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics, 2014, 46, 1258-1263.	9.4	269
102	The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma. Clinical Cancer Research, 2014, 20, 5601-5611.	3.2	53
104	Advancing clinical oncology through genome biology and technology. Genome Biology, 2014, 15, 427.	3.8	9
105	Prevalence and Implications ofTERTPromoter Mutation in Uveal and Conjunctival Melanoma and in Benign and Premalignant Conjunctival Melanocytic Lesions. , 2014, 55, 6024.		74
106	Genetic Markers in Adult High-Grade Gliomas. Seminars in Radiation Oncology, 2014, 24, 235-239.	1.0	2
107	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. British Journal of Cancer, 2014, 111, 2024-2032.	2.9	158
108	Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Research, 2014, 24, 761-774.	2.4	39
109	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. Neuro-Oncology, 2014, 16, 173-178.	0.6	23

#	Article	IF	Citations
110	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes and Diseases, 2014, 1, 75-86.	1.5	78
111	Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1985-1996.	1.1	933
112	Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. British Journal of Cancer, 2014, 110, 1058-1065.	2.9	111
113	Combined analysis of TERT , EGFR , and IDH status defines distinct prognostic glioblastoma classes. Neurology, 2014, 83, 1200-1206.	1.5	176
114	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nature Communications, 2014, 5, 3401.	5.8	163
115	High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. Journal of Hematology and Oncology, 2014, 7, 47.	6.9	66
116	Molecular Neuro-oncology and the Challenge of the Blood-Brain Barrier. Seminars in Oncology, 2014, 41, 438-445.	0.8	12
117	Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nature Reviews Cancer, 2014, 14, 651-661.	12.8	241
118	Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer. Clinical Cancer Research, 2014, 20, 4935-4948.	3.2	101
119	Genome-wide analysis of noncoding regulatory mutations in cancer. Nature Genetics, 2014, 46, 1160-1165.	9.4	469
120	Telomerase promoter mutations in cancer: an emerging molecular biomarker?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 119-133.	1.4	104
121	A case of primary diffuse leptomeningeal gliomatosis. Brain Tumor Pathology, 2014, 31, 177-181.	1.1	11
122	TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. Journal of Experimental and Clinical Cancer Research, 2014, 33, 33.	3.5	74
123	Telomerase in Bladder Cancer: Back to a Better Future?. European Urology, 2014, 65, 370-371.	0.9	9
124	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	3.9	176
125	BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. Journal of Clinical Oncology, 2014, 32, 2718-2726.	0.8	595
126	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH. Journal of Clinical Oncology, 2014, 32, 783-790.	0.8	356
127	TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	204

#	Article	IF	Citations
128	TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors. Journal of Neuro-Oncology, 2014, 120, 267-272.	1.4	17
129	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genetics, 2014, 46, 444-450.	9.4	871
130	TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E754-E765.	1.8	451
131	Telomerase-Dependent and Independent Telomere Maintenance and its Clinical Implications in Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1571-E1579.	1.8	34
132	Exploration of liver cancer genomes. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 340-349.	8.2	168
133	The absence of TERT promoter mutations in primary gastric cancer. Gene, 2014, 540, 266-267.	1.0	11
134	A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Therapeutic Advances in Vaccines, 2014, 2, 10-31.	2.7	77
135	TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. Journal of Investigative Dermatology, 2014, 134, 2251-2257.	0.3	105
136	Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nature Genetics, 2014, 46, 731-735.	9.4	161
137	Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. Endocrine-Related Cancer, 2014, 21, 653-661.	1.6	39
138	TERT promoter mutation in resectable hepatocellular carcinomas: A strong association with hepatitis C infection and absence of hepatitis B infection. International Journal of Surgery, 2014, 12, 659-665.	1.1	58
139	Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 1064-1072.	1.8	10
140	TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 685-687.	1.8	40
141	An overview of current and future treatment options for adults anaplastic oligodendroglial tumors. Expert Opinion on Orphan Drugs, 2014, 2, 831-840.	0.5	0
142	A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biology, 2015, 16, 231.	3.8	81
143	HMGA2 expression pattern and TERT mutations in tumors of the vulva. Oncology Reports, 2015, 33, 2675-2680.	1.2	17
144	Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas. Oncology Letters, 2015, 10, 163-167.	0.8	5
145	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathologica Communications, 2015, 3, 88.	2.4	42

#	Article	IF	Citations
146	CDKN2ALoss Is Associated With Shortened Overall Survival in Lower-Grade (World Health) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2015, 74, 442-452.	0.9	144
147	TERT promoter mutations are a rare event in gastrointestinal stromal tumors. SpringerPlus, 2015, 4, 836.	1.2	6
148	Mutations in <scp>TERT</scp> promoter and <scp>FGFR3</scp> and telomere length in bladder cancer. International Journal of Cancer, 2015, 137, 1621-1629.	2.3	81
149	Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. Oncotarget, 2015, 6, 43653-43666.	0.8	14
150	FrequentTERTPromoter Mutations in Ocular Surface Squamous Neoplasia. , 2015, 56, 5854.		23
151	TERT Promoter Mutations and Tert Expression in Early-Stage (T1N0M0) Non-Small Cell Lung Cancer (NSCLC). , 2015, 05, .		1
152	Cancer-associated TERT promoter mutations abrogate telomerase silencing. ELife, 2015, 4, .	2.8	208
153	Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget, 2015, 6, 20885-20901.	0.8	42
154	Personalized targeted therapy for esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2015, 21, 7648.	1.4	43
155	The Evolving Molecular Genetics of Low-grade Glioma. Advances in Anatomic Pathology, 2015, 22, 94-101.	2.4	89
156	Leiomyosarcoma With Alternative Lengthening of Telomeres Is Associated With Aggressive Histologic Features, Loss of ATRX Expression, and Poor Clinical Outcome. American Journal of Surgical Pathology, 2015, 39, 236-244.	2.1	80
157	Frequency of TERT Promoter Mutations in Prostate Cancer. Pathobiology, 2015, 82, 53-57.	1.9	38
158	Glioma Groups Based on 1p/19q,IDH, andTERTPromoter Mutations in Tumors. New England Journal of Medicine, 2015, 372, 2499-2508.	13.9	1,632
159	Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 809-827.	3.9	162
160	Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 789-808.	3.9	45
161	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncology, The, 2015, 16, e293-e302.	5.1	72
162	Biomarker-driven diagnosis of diffuse gliomas. Molecular Aspects of Medicine, 2015, 45, 87-96.	2.7	71
164	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathology and Applied Neurobiology, 2015, 41, 694-720.	1.8	83

#	Article	IF	Citations
165	Emerging roles of ATRX in cancer. Epigenomics, 2015, 7, 1365-1378.	1.0	54
166	TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis, 2015, 4, e176-e176.	2.1	81
167	Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. Nucleic Acids Research, 2015, 43, 5307-5317.	6.5	28
168	Oligodendrogliomas: a short history of clinical developments. CNS Oncology, 2015, 4, 281-285.	1.2	4
169	Advances in the treatment of newly diagnosed glioblastoma. BMC Medicine, 2015, 13, 293.	2.3	36
170	TERT promoter mutation designates biologically aggressive primary glioblastoma. Neuro-Oncology, 2015, 17, 5-6.	0.6	10
171	Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas. Cancer Discovery, 2015, 5, 239-244.	7.7	80
172	Telomere-Regulating Genes and the Telomere Interactome in Familial Cancers. Molecular Cancer Research, 2015, 13, 211-222.	1.5	29
173	BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	0.8	244
175	Reply to: â€œTERT promoter mutation during development of hepatoblastoma to hepatocellular carcinomaâ€. Journal of Hepatology, 2015, 62, 498-499.	1.8	0
176	Practical Molecular Pathologic Diagnosis of Infiltrating Gliomas. Surgical Pathology Clinics, 2015, 8, 49-61.	0.7	3
177	Ferritin in decompensated cirrhosis: Iron or inflammation?. Journal of Hepatology, 2015, 62, 499-500.	1.8	5
178	Genomic discoveries in adult astrocytoma. Current Opinion in Genetics and Development, 2015, 30, 17-24.	1.5	17
179	TERT promoter mutations and telomerase reactivation in urothelial cancer. Science, 2015, 347, 1006-1010.	6.0	255
180	Histone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferases. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 31-53.	2.3	31
181	TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. European Journal of Endocrinology, 2015, 172, 403-413.	1.9	115
182	Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Modern Pathology, 2015, 28, 303-311.	2.9	31
183	Tumor-specific mutations in low-frequency genes affect their functional properties. Journal of Neuro-Oncology, 2015, 122, 461-470.	1.4	13

#	Article	IF	Citations
184	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomedical Reports, 2015, 3, 443-446.	0.9	25
185	Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. Annals of Diagnostic Pathology, 2015, 19, 301-305.	0.6	35
186	Combined analysis of TERT , EGFR , and IDH status defines distinct prognostic glioblastoma classes. Neurology, 2015, 84, 2007-2007.	1.5	9
187	Telomere maintenance and the etiology of adult glioma. Neuro-Oncology, 2015, 17, 1445-1452.	0.6	70
188	Input of molecular analysis in medical management of primary brain tumor patients. Revue Neurologique, 2015, 171, 457-465.	0.6	2
189	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	3.9	237
190	Genetic Classification of Gliomas: Refining Histopathology. Cancer Cell, 2015, 28, 9-11.	7.7	40
191	TERT Promoter Mutations and TERT mRNA but Not FGFR3 Mutations Are Urinary Biomarkers in Han Chinese Patients With Urothelial Bladder Cancer. Oncologist, 2015, 20, 263-269.	1.9	28
192	A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix. Pathology Research and Practice, 2015, 211, 657-664.	1.0	40
193	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9704-9709.	3.3	317
194	Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 177-184.	1.4	59
195	TERT Promoter Mutations in Papillary Thyroid Microcarcinomas. Thyroid, 2015, 25, 1013-1019.	2.4	86
196	Applicable advances in the molecular pathology of glioblastoma. Brain Tumor Pathology, 2015, 32, 153-162.	1.1	12
197	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
198	Molecular profiling of gliomas: potential therapeutic implications. Expert Review of Anticancer Therapy, 2015, 15, 955-962.	1.1	22
199	Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications. Frontiers in Oncology, 2015, 5, 55.	1.3	186
200	A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. Experimental and Molecular Pathology, 2015, 98, 568-573.	0.9	14
201	Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World Journal of Gastroenterology, 2015, 21, 311.	1.4	53

#	Article	IF	Citations
202	Landscape of chromosomal copy number aberrations in gangliogliomas and dysembryoplastic neuroepithelial tumours. Neuropathology and Applied Neurobiology, 2015, 41, 743-755.	1.8	37
203	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade IIâ€“III diffuse gliomas. Acta Neuropathologica, 2015, 129, 585-596.	3.9	272
204	Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. European Journal of Cancer, 2015, 51, 969-976.	1.3	150
205	Anaplastic glioma: current treatment and management. Expert Review of Neurotherapeutics, 2015, 15, 601-620.	1.4	21
206	The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science, 2015, 348, 1036-1039.	6.0	451
207	Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 829-848.	3.9	503
208	Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. Cancer Genetics, 2015, 208, 367-373.	0.2	35
209	Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis. Advances in Anatomic Pathology, 2015, 22, 50-58.	2.4	78
210	Distinguishing Nested Variants of Urothelial Carcinoma From Benign Mimickers by TERT Promoter Mutation. American Journal of Surgical Pathology, 2015, 39, 127-131.	2.1	78
211	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. Journal of Neuro-Oncology, 2015, 123, 373-383.	1.4	14
212	Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade. Journal of Neuropathology and Experimental Neurology, 2015, 74, 241-249.	0.9	38
213	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Journal of Molecular Diagnostics, 2015, 17, 251-264.	1.2	1,566
214	Quantitative assessment of telomerase components in cancer cell lines. FEBS Letters, 2015, 589, 974-984.	1.3	68
215	Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro-Oncology, 2015, 17, 1231-1240.	0.6	102
216	Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics, 2015, 47, 458-468.	9.4	729
217	Molecular Markers in Low-Grade Gliomaâ€”Toward Tumor Reclassification. Seminars in Radiation Oncology, 2015, 25, 155-163.	1.0	62
218	Genetic variant near TERC influencing the risk of gliomas with older age at diagnosis in a Chinese population. Journal of Neuro-Oncology, 2015, 124, 57-64.	1.4	6
219	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology, 2015, 85, 1325-1331.	1.5	34

#	Article	IF	Citations
220	Non-canonical NF-Î²B signalling and ETS1/2 cooperatively drive C250T mutant TERT promoterÂactivation. Nature Cell Biology, 2015, 17, 1327-1338.	4.6	178
221	TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nature Genetics, 2015, 47, 1411-1414.	9.4	313
222	A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Research, 2015, 75, 4884-4894.	0.4	38
223	The role of neuropathology in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 531-549.	1.4	120
224	Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma. Molecular Cancer, 2015, 14, 134.	7.9	25
225	Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes and Development, 2015, 29, 2219-2224.	2.7	168
226	Proteomic profiling of patientâ€derived glioblastoma xenografts identifies a subset with activated <scp>EGFR</scp>: implications for drug development. Journal of Neurochemistry, 2015, 133, 730-738.	2.1	11
227	Mining the coding and non-coding genome for cancer drivers. Cancer Letters, 2015, 369, 307-315.	3.2	15
228	TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications, 2015, 6, 7207.	5.8	42
229	Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opinion on Investigational Drugs, 2015, 24, 1361-1379.	1.9	23
230	RAS proto-oncogene in medullary thyroid carcinoma. Endocrine-Related Cancer, 2015, 22, R235-R252.	1.6	83
231	Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell, 2015, 28, 318-328.	7.7	242
232	TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. British Journal of Cancer, 2015, 113, 1244-1248.	2.9	55
233	Preventing clonal evolutionary processes in cancer: Insights from mathematical models. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8843-8850.	3.3	17
234	Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma. Nutrition and Cancer, 2015, 67, 1120-1130.	0.9	18
235	Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncology, 2015, 1, 662.	3.4	68
236	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncology, 2015, 4, 287-294.	1.2	48
237	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. Archives of Pathology and Laboratory Medicine, 2015, 139, 1087-1093.	1.2	13

#	Article	IF	Citations
238	Emerging Interplay of Genetics and Epigenetics in Gliomas: A New Hope for Targeted Therapy. Seminars in Pediatric Neurology, 2015, 22, 14-22.	1.0	12
239	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an â€œintegratedâ€•diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 2015, 129, 133-146.	3.9	378
240	Genetics of familial melanoma: 20Âyears after <scp>CDKN</scp>2<scp>A</scp>. Pigment Cell and Melanoma Research, 2015, 28, 148-160.	1.5	121
241	Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells. Toxicology Letters, 2015, 232, 481-489.	0.4	28
242	TERT polymorphisms rs2853669 and rs7726159 influence on prostate cancer risk in Russian population. Tumor Biology, 2015, 36, 841-847.	0.8	23
243	Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization. Molecular and Cellular Endocrinology, 2015, 399, 288-295.	1.6	100
244	IDH1/2 mutation detection in gliomas. Brain Tumor Pathology, 2015, 32, 79-89.	1.1	44
245	Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). European Journal of Human Genetics, 2015, 23, 877-879.	1.4	27
246	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research, 2015, 21, 632-641.	3.2	525
247	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Modern Pathology, 2015, 28, 177-186.	2.9	107
248	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro-Oncology, 2015, 17, 45-52.	0.6	172
249	Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head and Neck, 2015, 37, 1642-1649.	0.9	66
250	Current Trends in High-Grade Gliomas. , 2016, , .		0
251	TERT Core Promotor Mutations in Early-Onset Bladder Cancer. Journal of Cancer, 2016, 7, 915-920.	1.2	31
252	TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas. Oncotarget, 2016, 7, 8712-8725.	0.8	63
253	Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene. Genes, 2016, 7, 50.	1.0	124
254	Telomerase Regulation from Beginning to the End. Genes, 2016, 7, 64.	1.0	69
255	Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications. Genes, 2016, 7, 38.	1.0	112

#	Article	IF	Citations
256	TERT Promoter Mutations in Soft Tissue Sarcomas. International Journal of Biological Markers, 2016, 31, 62-67.	0.7	14
257	Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Research, 2016, 5, 879.	0.8	159
258	Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget, 2016, 7, 21332-21346.	0.8	37
259	Redefining Management of Adult Low-Grade Gliomas. Journal of Oncology Practice, 2016, 12, 1244-1245.	2.5	0
260	Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology, 2016, 22, 9069.	1.4	126
261	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget, 2016, 7, 64615-64630.	0.8	22
262	Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. BioMed Research International, 2016, 2016, 1-14.	0.9	7
263	BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget, 2016, 7, 18346-18355.	0.8	109
264	Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis. OncoTargets and Therapy, 2016, Volume 9, 6965-6976.	1.0	27
265	Telomerase: The Devil Inside. Genes, 2016, 7, 43.	1.0	26
266	Telomerase Activation in Hematological Malignancies. Genes, 2016, 7, 61.	1.0	25
267	Lack of TERT Promoter Mutations in Human B-Cell Non-Hodgkin Lymphoma. Genes, 2016, 7, 93.	1.0	9
268	ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies. International Journal of Molecular Sciences, 2016, 17, 984.	1.8	104
269	Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis. PLoS ONE, 2016, 11, e0146803.	1.1	22
270	Evolving Molecular Genetics of Glioblastoma. Chinese Medical Journal, 2016, 129, 464-471.	0.9	41
271	The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes, 2016, 7, 66.	1.0	70
272	The Role of Telomeres and Telomere-associated Proteins as Components of Interactome in Cell-signaling Pathways. , 2016, , .		1
273	Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Medicine, 2016, 8, 69.	3.6	470

#	Article	IF	Citations
274	Association of <scp>TERT</scp> promoter mutations with telomerase expression in melanoma. Pigment Cell and Melanoma Research, 2016, 29, 391-393.	1.5	23
275	Kataegis Expression Signature in Breast Cancer Is Associated with Late Onset, Better Prognosis, and Higher HER2 Levels. Cell Reports, 2016, 16, 672-683.	2.9	33
276	Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and metaâ€analysis. Clinical Endocrinology, 2016, 85, 299-305.	1.2	42
277	Telomerase reverse transcriptase (<scp>TERT</scp>) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Histopathology, 2016, 69, 107-113.	1.6	54
278	An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations. Proteomics, 2016, 16, 417-426.	1.3	50
279	<scp>TERT</scp> promoter mutations in melanoma survival. International Journal of Cancer, 2016, 139, 75-84.	2.3	101
280	Role of micro<scp>RNA</scp>s Located on Chromosome Arm 10q in Malignant Gliomas. Brain Pathology, 2016, 26, 344-358.	2.1	26
281	Molecular Pathogenesis of Hepatocellular Carcinoma. Liver Cancer, 2016, 5, 290-302.	4.2	77
282	IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Scientific Reports, 2016, 6, 27569.	1.6	26
283	Treatment Strategies for Low-Grade Glioma in Adults. Journal of Oncology Practice, 2016, 12, 1235-1241.	2.5	66
284	Quantifying replicative senescence as a tumor suppressor pathway and a target for cancer therapy. Scientific Reports, 2016, 5, 17660.	1.6	17
285	Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes. Cytogenetic and Genome Research, 2016, 150, 194-207.	0.6	49
286	TERTPromoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma. Journal of Neuropathology and Experimental Neurology, 2017, 76, nlw106.	0.9	9
287	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
288	Copy Number Profiling of Brazilian Astrocytomas. G3: Genes, Genomes, Genetics, 2016, 6, 1867-1878.	0.8	12
289	Implications of telomeres and telomerase in endometrial pathology. Human Reproduction Update, 2016, 23, 166-187.	5.2	27
290	Genetics of glioma. , 0, , 1-23.		1
291	Role of Telomeres and Telomerase in Aging and Cancer. Cancer Discovery, 2016, 6, 584-593.	7.7	463

#	Article	IF	Citations
292	Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutantTERTpromoters. Transcription, 2016, 7, 44-49.	1.7	22
293	Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas. Journal of Neuro-Oncology, 2016, 128, 455-462.	1.4	9
294	Further understanding of the pathology of glioma: implications for the clinic. Expert Review of Neurotherapeutics, 2016, 16, 1055-1065.	1.4	32
295	Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma. Human Pathology, 2016, 55, 143-150.	1.1	15
296	Molecular genetics of thyroid cancer. Genetical Research, 2016, 98, e7.	0.3	6
297	Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist, 2016, 21, 214-219.	1.9	33
298	TERT promoter mutations in thyroid cancer. Endocrine-Related Cancer, 2016, 23, R143-R155.	1.6	301
299	Radiotherapy plus concomitant temozolomide in primary gliosarcoma. Journal of Neuro-Oncology, 2016, 128, 341-348.	1.4	26
300	Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death and Disease, 2016, 7, e2213-e2213.	2.7	86
301	Induced Pluripotent Stem Cells Meet Genome Editing. Cell Stem Cell, 2016, 18, 573-586.	5.2	398
302	CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	3.2	448
303	Molecular classification of gliomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 97-120.	1.0	90
304	Stop pulling my strings â€" what telomeres taught us about the DNA damage response. Nature Reviews Molecular Cell Biology, 2016, 17, 364-378.	16.1	148
305	DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clinical Cancer Research, 2016, 22, 3903-3914.	3.2	54
306	Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. Journal of Molecular Diagnostics, 2016, 18, 620-634.	1.2	42
307	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications, 2016, 4, 79.	2.4	189
308	High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 427-434.	1.4	38
309	In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 687-696.	1.4	40

#	Article	IF	Citations
310	Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation. Cancer Discovery, 2016, 6, 1276-1291.	7.7	127
311	Astrocytic gliomas WHO grades II and III. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 345-360.	1.0	11
312	Low-grade and anaplastic oligodendroglioma. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 361-380.	1.0	26
313	Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. Cancer and Metastasis Reviews, 2016, 35, 457-474.	2.7	48
314	TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver diseaseâ€related hepatocellular carcinoma. International Journal of Cancer, 2016, 139, 2512-2518.	2.3	36
315	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathologica, 2016, 132, 625-634.	3.9	85
316	HumanTERTpromoter mutation enables survival advantage fromMGMTpromoter methylation inIDH1wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology, 2017, 19, now189.	0.6	65
317	TERT promoter mutations and prognosis in solitary fibrous tumor. Modern Pathology, 2016, 29, 1511-1522.	2.9	88
318	Avian Leukosis Virus Activation of an Antisense RNA Upstream of TERT in B-Cell Lymphomas. Journal of Virology, 2016, 90, 9509-9517.	1.5	3
319	A novel truncated form of HMGA2 in tumors of the ovaries. Oncology Letters, 2016, 12, 1559-1563.	0.8	7
320	Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. Surgical Pathology Clinics, 2016, 9, 379-390.	0.7	4
321	TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocrine-Related Cancer, 2016, 23, 813-823.	1.6	81
322	A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters. Journal of the American Chemical Society, 2016, 138, 13673-13692.	6.6	91
323	hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas. Journal of Neuro-Oncology, 2016, 130, 79-87.	1.4	26
324	Genomic Landscape of Brain Tumors. , 2016, , 653-663.		0
325	Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Research, 2016, 76, 6680-6689.	0.4	55
326	A somatic reference standard for cancer genome sequencing. Scientific Reports, 2016, 6, 24607.	1.6	64
327	Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discovery, 2016, 6, 1215-1229.	7.7	81

#	Article	IF	Citations
328	TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. Scientific Reports, 2016, 6, 29714.	1.6	13
329	Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 320-329.	3.3	17
330	Molecular Mechanisms of Hepatocellular Carcinoma. , 2016, , 43-63.		2
331	Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. Current Opinion in Oncology, 2016, 28, 494-501.	1.1	62
332	Negative selection maintains transcription factor binding motifs in human cancer. BMC Genomics, 2016, 17, 395.	1.2	16
333	Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma. American Journal of Surgical Pathology, 2016, 40, 1291-1295.	2.1	14
334	Acquired <scp>TERT</scp> promoter mutations stimulate <scp>TERT</scp> transcription in mantle cell lymphoma. American Journal of Hematology, 2016, 91, 481-485.	2.0	28
335	Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes. Genes Chromosomes and Cancer, 2016, 55, 291-310.	1.5	107
336	The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. International Journal of Cancer, 2016, 139, 414-423.	2.3	50
337	Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Modern Pathology, 2016, 29, 1012-1027.	2.9	54
338	Radiobiology of Glioblastoma. Current Clinical Pathology, 2016, , .	0.0	2
339	Basic Knowledge of Glioblastoma Radiobiology. Current Clinical Pathology, 2016, , 139-153.	0.0	0
340	DNA repair mechanisms and their clinical impact in glioblastoma. Mutation Research - Reviews in Mutation Research, 2016, 769, 19-35.	2.4	128
341	New prospects for targeting telomerase beyond the telomere. Nature Reviews Cancer, 2016, 16, 508-524.	12.8	104
342	Telomerase in hematologic malignancies. Current Opinion in Hematology, 2016, 23, 346-353.	1.2	12
343	Patients treatment with neuroglioma by teniposide and semustine and its influence on Twist and E-cadherin expression. Saudi Pharmaceutical Journal, 2016, 24, 299-304.	1.2	3
344	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 2016, 65, 1031-1042.	1.8	219
345	AN in vitro evaluation of a carmustine-loaded Nano-co-Plex for potential magnetic-targeted intranasal delivery to the brain. International Journal of Pharmaceutics, 2016, 500, 196-209.	2.6	41

#	Article	IF	Citations
346	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer Research, 2016, 76, 525-534.	0.4	93
347	Role of non-coding sequence variants in cancer. Nature Reviews Genetics, 2016, 17, 93-108.	7.7	420
348	The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR. Genetic Testing and Molecular Biomarkers, 2016, 20, 90-93.	0.3	12
349	ORegAnno 3.0: a community-driven resource for curated regulatory annotation. Nucleic Acids Research, 2016, 44, D126-D132.	6.5	142
350	Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. Journal of Gastroenterology, 2016, 51, 473-486.	2.3	89
351	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. Journal of Biological Chemistry, 2016, 291, 9690-9699.	1.6	45
352	Next-generation molecular diagnostics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 121-130.	1.0	1
353	Genotyping low-grade gliomas among Hispanics. Neuro-Oncology Practice, 2016, 3, 164-172.	1.0	4
354	Reactivation of telomerase in cancer. Cellular and Molecular Life Sciences, 2016, 73, 1659-1670.	2.4	154
355	TERT mutation in glioma: Frequency, prognosis and risk. Journal of Clinical Neuroscience, 2016, 26, 57-62.	0.8	40
356	Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagnostic Pathology, 2016, 11, 21.	0.9	52
357	Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications. Annals of Diagnostic Pathology, 2016, 21, 7-11.	0.6	38
358	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	13.5	1,695
359	Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathologica, 2016, 131, 847-863.	3.9	143
360	Central Nervous System: Progress of Today and a Preview of Tomorrow. International Journal of Radiation Oncology Biology Physics, 2016, 94, 425-427.	0.4	3
361	Understanding TERT Promoter Mutations: A Common Path to Immortality. Molecular Cancer Research, 2016, 14, 315-323.	1.5	222
363	Understanding inherited genetic risk of adult glioma â€“ a review. Neuro-Oncology Practice, 2016, 3, 10-16.	1.0	62
364	Epidemiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 3-18.	1.0	15

#	Article	IF	Citations
365	Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Human Pathology, 2016, 53, 8-13.	1.1	31
366	Classification based on mutations ofTERTpromoter andIDHcharacterizes subtypes in grade II/III gliomas. Neuro-Oncology, 2016, 18, 1099-1108.	0.6	93
367	High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Modern Pathology, 2016, 29, 511-515.	2.9	34
368	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
369	High incidence of TERT mutation in brain tumor cell lines. Brain Tumor Pathology, 2016, 33, 222-227.	1.1	26
370	Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro-Oncology, 2016, 18, 379-387.	0.6	101
371	TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. Tumor Biology, 2016, 37, 7907-7913.	0.8	32
372	An epigenetic gateway to brain tumor cell identity. Nature Neuroscience, 2016, 19, 10-19.	7.1	76
373	TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. Journal of Neuro-Oncology, 2016, 126, 441-446.	1.4	30
374	Emerging Bladder Cancer Biomarkers and Targets of Therapy. Urologic Clinics of North America, 2016, 43, 63-76.	0.8	21
375	Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application. Journal of Neurosurgery, 2016, 124, 1611-1618.	0.9	8
376	Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. Tumor Biology, 2016, 37, 4901-4907.	0.8	13
377	TERT promoter mutations in primary liver tumors. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 9-14.	0.7	78
378	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 2016, 18, 388-400.	0.6	143
379	Preoperative Assessment of TERT Promoter Mutation on Thyroid Core Needle Biopsies Supports Diagnosis of Malignancy and Addresses Surgical Strategy. Hormone and Metabolic Research, 2016, 48, 157-162.	0.7	25
380	Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis. Molecular Neurobiology, 2016, 53, 2726-2732.	1.9	11
381	Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors. Neuro-Oncology, 2016, 18, 350-360.	0.6	45
382	Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology, 2016, 18, 16-26.	0.6	221

#	Article	IF	Citations
383	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology, 2017, 14, 115-128.	12.5	95
384	TERT Genetic Mutations as Prognostic Marker in Glioma. Molecular Neurobiology, 2017, 54, 3665-3669.	1.9	11
385	Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Gliomaâ€Tailored Gene Panel. Brain Pathology, 2017, 27, 146-159.	2.1	130
386	Fibroblast activation and senescence in oral cancer. Journal of Oral Pathology and Medicine, 2017, 46, 82-88.	1.4	34
387	The new WHO 2016 classification of brain tumorsâ€"what neurosurgeons need to know. Acta Neurochirurgica, 2017, 159, 403-418.	0.9	85
388	The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. Journal of Neuro-Oncology, 2017, 132, 1-11.	1.4	35
389	TERT biology and function in cancer: beyond immortalisation. Journal of Molecular Endocrinology, 2017, 58, R129-R146.	1.1	68
390	Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nature Genetics, 2017, 49, 349-357.	9.4	476
391	Telomeres in cancer: tumour suppression and genome instability. Nature Reviews Molecular Cell Biology, 2017, 18, 175-186.	16.1	505
392	Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head and Neck, 2017, 39, 1131-1137.	0.9	40
393	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Current Neurology and Neuroscience Reports, 2017, 17, 19.	2.0	87
394	Non-coding genetic variation in cancer. Current Opinion in Systems Biology, 2017, 1, 9-15.	1.3	42
395	Integration of highâ€risk human papillomavirus into cellular cancerâ€related genes in head and neck cancer cell lines. Head and Neck, 2017, 39, 840-852.	0.9	34
396	Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma. Molecular Cancer Research, 2017, 15, 532-540.	1.5	23
397	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica, 2017, 133, 1001-1016.	3.9	245
398	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathologica, 2017, 134, 507-516.	3.9	144
399	Altered TERT promoter and other genomic regulatory elements: occurrence and impact. International Journal of Cancer, 2017, 141, 867-876.	2.3	20
400	Identification of somatic <scp>TERT</scp> promoter mutations in familial nonmedullary thyroid carcinomas. Clinical Endocrinology, 2017, 87, 394-399.	1.2	23

#	Article	IF	Citations
401	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
402	Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics, 2017, 49, 825-833.	9.4	55
403	Induction of senescence in primary glioblastoma cells by serum and TGFÎ². Scientific Reports, 2017, 7, 2156.	1.6	17
404	Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 761-767.	1.4	29
405	Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathologica Communications, 2017, 5, 18.	2.4	47
406	Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma. Gastroenterology, 2017, 153, 249-262.e2.	0.6	100
407	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 2017, 19, 1183-1194.	0.6	31
408	Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications. Neurotherapeutics, 2017, 14, 372-384.	2.1	70
409	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. Journal of Neuro-Oncology, 2017, 134, 541-549.	1.4	109
410	Detection of Aberrant TERT Promoter Methylation by Combined Bisulfite Restriction Enzyme Analysis for Cancer Diagnosis. Journal of Molecular Diagnostics, 2017, 19, 378-386.	1.2	12
411	Molecular mechanisms and therapeutic targets in pediatric brain tumors. Science Signaling, 2017, 10, .	1.6	53
412	Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Molecular and Cellular Endocrinology, 2017, 448, 34-40.	1.6	30
413	Control of Cellular Aging, Tissue Function, and Cancer by p53 Downstream of Telomeres. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026088.	2.9	45
414	The Effect of Molecular Diagnostics on the Treatment of Glioma. Current Oncology Reports, 2017, 19, 26.	1.8	40
415	TERT promoter mutations in telomere biology. Mutation Research - Reviews in Mutation Research, 2017, 771, 15-31.	2.4	155
416	The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion on Drug Safety, 2017, 16, 277-287.	1.0	19
417	Isocitrate dehydrogenaseâ€mutant glioma: Evolving clinical and therapeutic implications. Cancer, 2017, 123, 4535-4546.	2.0	103
418	Drug Discovery and Chemical Biology of Cancer Epigenetics. Cell Chemical Biology, 2017, 24, 1120-1147.	2.5	47

#	Article	IF	Citations
419	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroupsâ€"A meta-analysis of aggregate data. Critical Reviews in Oncology/Hematology, 2017, 120, 1-9.	2.0	44
420	Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 641-649.	1.4	7
421	BRD4 inhibitors block telomere elongation. Nucleic Acids Research, 2017, 45, 8403-8410.	6.5	33
422	Telomerase reverse transcriptase (TERT) â€•enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and <scp>DNA</scp> damage responses in glioblastoma. Journal of Neurochemistry, 2017, 143, 671-683.	2.1	52
423	New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. Neuroradiology, 2017, 59, 1223-1231.	1.1	12
424	Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. Cancer Research, 2017, 77, 6097-6108.	0.4	46
425	Molecular Pathology of Glioblastoma- An Update. Current Cancer Research, 2017, , 19-55.	0.2	0
426	Paradoxical prognostic impact of <scp>TERT</scp> promoter mutations in gliomas depends on different histological and genetic backgrounds. CNS Neuroscience and Therapeutics, 2017, 23, 790-797.	1.9	17
427	Molecular Pathogenesis of Liver Cancer. Journal of Gastrointestinal Cancer, 2017, 48, 222-224.	0.6	5
428	Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocrine-Related Cancer, 2017, 24, R315-R334.	1.6	94
429	T2â€"FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clinical Cancer Research, 2017, 23, 6078-6085.	3.2	285
430	Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis. Journal of Neuro-Oncology, 2017, 135, 381-390.	1.4	21
431	Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science, 2017, 357, 1416-1420.	6.0	224
432	Mutation of the TERT promoter leads to poor prognosis of patients with non-small cell lung cancer. Oncology Letters, 2017, 14, 1609-1614.	0.8	29
433	Telomeres and telomerase in prostate cancer development and therapy. Nature Reviews Urology, 2017, 14, 607-619.	1.9	85
434	Characterization of gliomas: from morphology to molecules. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 257-269.	1.4	86
435	Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. British Journal of Cancer, 2017, 117, 583-587.	2.9	70
436	Pediatric High Grade Glioma. Current Cancer Research, 2017, , 241-266.	0.2	1

#	Article	IF	Citations
437	Next-Generation Sequencing in Glioblastoma Personalized Therapy. Current Cancer Research, 2017, , 161-190.	0.2	1
438	The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC). World Journal of Surgical Oncology, 2017, 15, 114.	0.8	10
439	Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infectious Agents and Cancer, 2017, 12, 27.	1.2	40
441	Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma. Medicine (United States), 2017, 96, e5766.	0.4	47
442	Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer. JAMA Oncology, 2017, 3, 202.	3.4	217
443	Molecular pathology of paediatric central nervous system tumours. Journal of Pathology, 2017, 241, 159-172.	2.1	51
444	Study of <i>hTERT</i> and Histone 3 Mutations in Medulloblastoma. Pathobiology, 2017, 84, 108-113.	1.9	7
445	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	3.4	191
446	Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas. Journal of Cellular Biochemistry, 2017, 118, 2064-2071.	1.2	5
447	IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas. Neurosurgery, 2017, 64, 134-138.	0.6	27
448	Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes. Cell Reports, 2017, 21, 3700-3707.	2.9	68
449	Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1757-1764.	1.8	37
450	Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro-Oncology, 2017, 19, 546-557.	0.6	86
451	Epigenetic dysregulation in brain tumors and neurodevelopment. , 2017, , 261-276.		0
452	Telomeres and Telomerase in Neuroblastoma. , 0, , .		1
453	Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme. Oncology Letters, 2017, 14, 8213-8219.	0.8	13
454	The role of IDH1/2 mutations in the pathogenesis of secondary glioblastomas. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2017, 53, .	0.3	6
455	hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer. Molecular Medicine Reports, 2017, 16, 441-446.	1.1	17

#	Article	IF	Citations
456	Telomere protein complexes and their role in lymphoid malignancies. Frontiers in Bioscience - Scholar, 2017, 9, 17-30.	0.8	3
457	Current Insights to Regulation and Role of Telomerase in Human Diseases. Antioxidants, 2017, 6, 17.	2.2	51
458	The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathologica Communications, 2017, 5, 62.	2.4	71
459	Human glioma stem-like cells induce malignant transformation of bone marrow mesenchymal stem cells by activating TERT expression. Oncotarget, 2017, 8, 104418-104429.	0.8	11
460	Insights From Molecular Profiling of Adult Glioma. Journal of Clinical Oncology, 2017, 35, 2386-2393.	0.8	53
461	Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells. Neoplasma, 2017, 64, 700-708.	0.7	25
462	Uncommon Human Telomerase Reverse Transcriptase Promoter Mutations Are Associated With Poor Survival in Ovarian Clear Cell Carcinoma. American Journal of Clinical Pathology, 2018, 149, 352-361.	0.4	6
463	Oral Cancer: Recent Developments and Future Challenges. , 2018, , 105-118.		1
464	Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. Scientific Reports, 2018, 8, 3881.	1.6	18
465	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. Advances in Anatomic Pathology, 2018, 25, 143-171.	2.4	31
466	Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. International Journal of Cancer, 2018, 143, 1153-1161.	2.3	30
467	Reconstructing the molecular life history of gliomas. Acta Neuropathologica, 2018, 135, 649-670.	3.9	61
468	Association between mutant IDHs and tumorigenesis in gliomas. Medical Molecular Morphology, 2018, 51, 194-198.	0.4	9
469	Current state of immunotherapy for glioblastoma. Nature Reviews Clinical Oncology, 2018, 15, 422-442.	12.5	873
470	Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Pathology Research and Practice, 2018, 214, 881-888.	1.0	33
471	Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival. Npj Genomic Medicine, 2018, 3, 1.	1.7	79
472	Temozolomide-associated hypermutation in gliomas. Neuro-Oncology, 2018, 20, 1300-1309.	0.6	130
473	TERT promoter mutation in adult granulosa cell tumor of the ovary. Modern Pathology, 2018, 31, 1107-1115.	2.9	49

#	Article	IF	Citations
474	Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. Scientific Reports, 2018, 8, 1917.	1.6	50
475	IW-Scoring: an Integrative Weighted Scoring framework for annotating and prioritizing genetic variations in the noncoding genome. Nucleic Acids Research, 2018, 46, e47-e47.	6.5	30
476	Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nature Communications, 2018, 9, 579.	5.8	140
478	Molecular Biomarkers in the Clinical Management of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030601.	2.9	11
479	Dysfunctional telomeres and hematological disorders. Differentiation, 2018, 100, 1-11.	1.0	16
480	Precision oncology in the age of integrative genomics. Nature Biotechnology, 2018, 36, 46-60.	9.4	104
481	HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis. Nature Communications, 2018, 9, 100.	5.8	38
482	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 472-483.	0.6	42
483	SNPitty. Journal of Molecular Diagnostics, 2018, 20, 166-176.	1.2	13
484	Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues. Journal of Molecular Diagnostics, 2018, 20, 240-252.	1.2	32
485	Telomere sequence content can be used to determine ALT activity in tumours. Nucleic Acids Research, 2018, 46, 4903-4918.	6.5	40
486	Telomerase promoter mutations and copy number alterations in solitary fibrous tumours. Journal of Clinical Pathology, 2018, 71, 832-839.	1.0	14
487	Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nature Reviews Urology, 2018, 15, 386-393.	1.9	48
488	Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma. Cancer Research, 2018, 78, 2966-2977.	0.4	63
489	The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle, 2018, 17, 702-711.	1.3	36
490	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	3.9	190
491	Genomic landscape in gastroenteropancreatic neuroendocrine neoplasms and its usefulness in improving the prognostic evaluation. Diagnostic Histopathology, 2018, 24, 111-119.	0.2	2
492	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 2018, 24, 4771-4784.	3.2	29

#	Article	IF	Citations
493	Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft. Molecular Cancer Therapeutics, 2018, 17, 1187-1195.	1.9	33
494	What's New in Grade II and Grade III Gliomas?. Seminars in Neurology, 2018, 38, 041-049.	0.5	1
495	New Directions in the Treatment of Glioblastoma. Seminars in Neurology, 2018, 38, 050-061.	0.5	33
496	When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM. Current Neurology and Neuroscience Reports, 2018, 18, 15.	2.0	10
497	Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors. Cellular and Molecular Neurobiology, 2018, 38, 393-419.	1.7	19
498	TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2018, 40, 1-6.	0.3	11
499	Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Journal of Neurosurgery, 2018, 128, 1102-1114.	0.9	26
500	Theoretical Prediction of Adsorption Properties of Carmustine Drug on Various Sites of the Outer Surface of the Single-Walled Boron Nitride Nanotube and Investigation of Urea Effect on Drug Delivery by DFT and MD. Journal of Cluster Science, 2018, 29, 93-99.	1.7	10
501	Correlation between telomerase and mTOR pathway in cancer stem cells. Gene, 2018, 641, 235-239.	1.0	38
502	Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. Modern Pathology, 2018, 31, 418-428.	2.9	75
503	Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. Human Pathology, 2018, 72, 127-134.	1.1	21
504	TERT promoter hotspot mutations in breast cancer. Breast Cancer, 2018, 25, 292-296.	1.3	29
505	Astrocytic and Oligodendroglial Tumors. , 2018, , 91-123.		1
506	Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. Translational Research, 2018, 193, 54-71.	2.2	156
507	Telomerase reverse transcriptase promoter alterations across cancer types as detected by nextâ€generation sequencing: A clinical and molecular analysis of 423 patients. Cancer, 2018, 124, 1288-1296.	2.0	21
508	Immuno-oncology from the perspective of somatic evolution. Seminars in Cancer Biology, 2018, 52, 75-85.	4.3	15
509	Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma. British Journal of Cancer, 2018, 118, 98-105.	2.9	52
510	A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. Journal of Clinical Pathology, 2018, 71, 323-329.	1.0	10

#	Article	IF	Citations
511	Glioblastoma: new therapeutic strategies to address cellular and genomic complexity. Oncotarget, 2018, 9, 9540-9554.	0.8	60
512	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	3.9	130
513	IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas. Medicine (United States), 2018, 97, e13675.	0.4	11
514	Significance of TERT and ATRX mutations in glioma. Oncology Letters, 2019, 17, 95-102.	0.8	24
515	Survivorship in Neuro-Oncology: Improving Care by Advancing Science. Neuro-Oncology, 2018, 20, NP-NP.	0.6	0
516	Updates in prognostic markers for gliomas. Neuro-Oncology, 2018, 20, vii17-vii26.	0.6	78
517	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies (Review). Biomedical Reports, 2018, 10, 3-9.	0.9	7
518	Life History Trade-Offs in Tumors. Current Pathobiology Reports, 2018, 6, 201-207.	1.6	14
519	Absence of TERT promoter mutations in colorectal precursor lesions and cancer. Genetics and Molecular Biology, 2018, 41, 82-84.	0.6	4
520	Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration. Cell Communication and Signaling, 2018, 16, 60.	2.7	23
521	TERT, the target?. Neuro-Oncology, 2018, 20, 1561-1562.	0.6	0
522	ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. PLoS ONE, 2018, 13, e0204159.	1.1	48
523	Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. Cancer Genomics and Proteomics, 2018, 15, 421-436.	1.0	9
524	Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. Acta Neuropathologica Communications, 2018, 6, 95.	2.4	13
525	BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study. World Neurosurgery, 2018, 120, e1225-e1233.	0.7	16
526	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Medical Sciences (Basel, Switzerland), 2018, 6, 85.	1.3	9
527	TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Acta Neuropathologica Communications, 2018, 6, 106.	2.4	18
528	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica, 2018, 136, 793-803.	3.9	195

#	Article	IF	Citations
529	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. PLoS ONE, 2018, 13, e0203570.	1.1	11
530	Disruption of the Î²1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. Cancer Cell, 2018, 34, 513-528.e8.	7.7	103
531	Different patterns of clonal evolution among different sarcoma subtypes followed for up to 25 years. Nature Communications, 2018, 9, 3662.	5.8	13
532	Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas. International Journal of Molecular Sciences, 2018, 19, 608.	1.8	9
533	Reproducibility of the NanoString 22â€gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Neuropathology, 2018, 38, 475-483.	0.7	26
534	TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. Journal of Neuro-Oncology, 2018, 139, 671-678.	1.4	51
535	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications, 2018, 9, 2087.	5.8	124
536	An Activity Switch in Human Telomerase Based on RNA Conformation and Shaped by TCAB1. Cell, 2018, 174, 218-230.e13.	13.5	64
537	The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review. Clinical Neurology and Neurosurgery, 2018, 170, 120-126.	0.6	26
538	Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. Modern Pathology, 2018, 31, 1661-1674.	2.9	63
539	An Overview of Molecular Genetics of Brain Tumors. , 2018, , 249-255.		1
540	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	2.8	118
541	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. World Neurosurgery, 2018, 116, 495-504.	0.7	13
542	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurologic Clinics, 2018, 36, 421-437.	0.8	9
543	hTERT promoter mutations in chondrosarcomas associate with progression and disease-related mortality. Modern Pathology, 2018, 31, 1834-1841.	2.9	10
544	Genotype-targeted local therapy of glioma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8388-E8394.	3.3	40
545	Telomere Maintenance Mechanisms in Cancer. Genes, 2018, 9, 241.	1.0	91
546	Current Perspectives of Telomerase Structure and Function in Eukaryotes with Emerging Views on Telomerase in Human Parasites. International Journal of Molecular Sciences, 2018, 19, 333.	1.8	26

#	Article	IF	Citations
547	Telomere Length Dynamics and the Evolution of Cancer Genome Architecture. International Journal of Molecular Sciences, 2018, 19, 482.	1.8	48
548	Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. International Journal of Molecular Sciences, 2018, 19, 1765.	1.8	44
549	A Novel Long Non-Coding RNA in the hTERT Promoter Region Regulates hTERT Expression. Non-coding RNA, 2018, 4, 1.	1.3	28
550	The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRIâ€derived and clinical features, predict adult primary glioblastoma survival. Cancer Medicine, 2018, 7, 3704-3712.	1.3	22
551	<scp>TERT</scp> promoter mutations in solitary fibrous tumour. Histopathology, 2018, 73, 843-851.	1.6	47
552	Clinical and immunological correlates of long term survival in glioblastoma. Wspolczesna Onkologia, 2018, 2018, 81-85.	0.7	15
553	Suppression of PROX1â€mediated TERT expression in hepatitis B viral hepatocellular carcinoma. International Journal of Cancer, 2018, 143, 3155-3168.	2.3	13
554	TERTpromoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro-Oncology, 2018, 20, 1584-1593.	0.6	88
555	Nigella sativa L. and Its Bioactive Constituents as Hepatoprotectant: A Review. Current Pharmaceutical Biotechnology, 2018, 19, 43-67.	0.9	21
556	Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. Journal of Biomedical Science, 2018, 25, 22.	2.6	172
557	Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia. Journal of Translational Medicine, 2018, 16, 77.	1.8	8
558	Essential roles of telomerase reverse transcriptase <scp>hTERT</scp> in cancer stemness and metastasis. FEBS Letters, 2018, 592, 2023-2031.	1.3	84
559	Knockdown of GA-binding protein subunit Î²1 inhibits cell proliferation via p21 induction in renal cell carcinoma. International Journal of Oncology, 2018, 53, 886-894.	1.4	6
560	An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiformeâ€”Role in Pathogenesis and Therapeutic Perspective. International Journal of Molecular Sciences, 2018, 19, 889.	1.8	65
561	Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1. Nature Communications, 2018, 9, 3183.	5.8	52
562	Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series. Neuro-Oncology, 2018, 20, 1625-1633.	0.6	12
563	Population Dynamics and Evolution of Cancer Cells. Handbook of Statistics, 2018, , 3-35.	0.4	0
564	The expression of telomere-related proteins and DNA damage response and their association with telomere length in colorectal cancer in Saudi patients. PLoS ONE, 2018, 13, e0197154.	1.1	8

#	Article	IF	Citations
565	Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors. Hepatology Communications, 2018, 2, 718-731.	2.0	49
566	TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma. Endocrine, 2018, 61, 489-498.	1.1	13
567	The additive to background assumption in cancer risk assessment: A reappraisal. Environmental Research, 2018, 166, 175-204.	3.7	18
568	TERT promoter mutation subtypes and survival in stage I and II melanoma patients. International Journal of Cancer, 2019, 144, 1027-1036.	2.3	44
569	Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. Neuro-Oncology, 2019, 21, 47-58.	0.6	28
570	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology, 2019, 29, 85-96.	2.1	88
571	The Fusion Oncogene FUS-CHOP Drives Sarcomagenesis of High-Grade Spindle Cell Sarcomas in Mice. Sarcoma, 2019, 2019, 1-14.	0.7	9
572	Saturation mutagenesis of twenty disease-associated regulatory elements at single base-pair resolution. Nature Communications, 2019, 10, 3583.	5.8	152
573	Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Medicine, 2019, 8, 5831-5839.	1.3	57
574	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. , 2019, , .		0
575	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. Expert Review of Neurotherapeutics, 2019, 19, 663-677.	1.4	3
576	Molecular changes in solitary fibrous tumor progression. Journal of Molecular Medicine, 2019, 97, 1413-1425.	1.7	47
577	Correlation between TERT C228T and clinic-pathological features in pediatric papillary thyroid carcinoma. Science China Life Sciences, 2019, 62, 1563-1571.	2.3	16
578	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	5.8	205
579	Quantitative proteomics reveals reduction of endocytic machinery components in gliomas. EBioMedicine, 2019, 46, 32-41.	2.7	26
580	Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Science, 2019, 110, 2247-2257.	1.7	42
581	Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro-Oncology, 2019, 21, 1458-1469.	0.6	47
582	The role of telomeres and telomerase in cirrhosis and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 544-558.	8.2	154

#	Article	IF	Citations
583	The role of biomarkers in the diagnosis and treatment of oligodendrogliomas. , 2019, , 109-115.		1
584	Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study. Journal of Cancer, 2019, 10, 2397-2406.	1.2	13
585	Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 2019, 80, 101896.	3.4	386
586	Association between extent of resection on survival in adult brainstem high-grade glioma patients. Journal of Neuro-Oncology, 2019, 145, 479-486.	1.4	15
587	The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathologica Communications, 2019, 7, 156.	2.4	47
588	The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA. Frontiers in Oncology, 2019, 9, 952.	1.3	6
589	Joyce and the Law. Ed. by Jonathan Goldman. Forum for Modern Language Studies, 2019, 55, 246-246.	0.2	1
590	What Do Neighbors Tell About You: The Local Context of Cis-Regulatory Modules Complicates Prediction of Regulatory Variants. Frontiers in Genetics, 2019, 10, 1078.	1.1	3
591	The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas. Acta Neuropathologica Communications, 2019, 7, 175.	2.4	8
592	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. Cancer Cell, 2019, 36, 674-689.e6.	7.7	52
593	<scp>ATRX</scp> loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO Journal, 2019, 38, e96659.	3.5	71
594	Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma. International Journal of Molecular Sciences, 2019, 20, 200.	1.8	30
595	Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathologica Communications, 2019, 7, 139.	2.4	12
596	Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications. Frontiers in Oncology, 2019, 9, 779.	1.3	78
597	Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation. European Journal of Cancer, 2019, 120, 10-19.	1.3	7
598	PLEKHS1: A new molecular marker predicting risk of progression of nonâ€‘muscleâ€‘invasive bladder cancer. Oncology Letters, 2019, 18, 3471-3480.	0.8	10
599	Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells. PLoS ONE, 2019, 14, e0211046.	1.1	10
600	Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy. Molecules, 2019, 24, 429.	1.7	214

#	Article	IF	Citations
601	TERTgene: its function and dysregulation in cancer. Journal of Clinical Pathology, 2019, 72, 281-284.	1.0	63
602	Mutational signatures and the genomic landscape of betel quid chewingâ€associated tongue carcinoma. Cancer Medicine, 2019, 8, 701-711.	1.3	7
603	Accelerated progression of IDH mutant glioma after first recurrence. Neuro-Oncology, 2019, 21, 669-677.	0.6	38
604	Revisiting Telomere Shortening in Cancer. Cells, 2019, 8, 107.	1.8	98
605	Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine, 2019, 44, 431-438.	2.7	41
606	Scarcity of Recurrent Regulatory Driver Mutations in Colorectal Cancer Revealed by Targeted Deep Sequencing. JNCI Cancer Spectrum, 2019, 3, pkz012.	1.4	2
607	Impact of cancer mutational signatures on transcription factor motifs in the human genome. BMC Medical Genomics, 2019, 12, 64.	0.7	11
608	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.2	4
609	Genomics-Enabled Precision Medicine for Cancer. Cancer Treatment and Research, 2019, 178, 137-169.	0.2	9
610	Genetic and molecular epidemiology of adult diffuse glioma. Nature Reviews Neurology, 2019, 15, 405-417.	4.9	437
611	Molecular pathology of tumors of the central nervous system. Annals of Oncology, 2019, 30, 1265-1278.	0.6	129
612	Telomerase and Telomeres in Endometrial Cancer. Frontiers in Oncology, 2019, 9, 344.	1.3	20
613	Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. Cell Chemical Biology, 2019, 26, 1110-1121.e4.	2.5	41
614	Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro-Oncology, 2019, 21, 1164-1174.	0.6	12
615	Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes and Development, 2019, 33, 591-609.	2.7	303
616	Diverse regulatory manners of human telomerase reverse transcriptase. Cell Communication and Signaling, 2019, 17, 63.	2.7	24
617	The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01. Brain Tumor Research and Treatment, 2019, 7, 1.	0.4	19
618	In perspective: An update on telomere targeting in cancer. Molecular Carcinogenesis, 2019, 58, 1581-1588.	1.3	41

#	Article	IF	Citations
619	Neuro-oncology. , 2019, , 391-457.		0
620	Case of metastatic glioblastoma with primitive neuronal component to the lung. Neuropathology, 2019, 39, 218-223.	0.7	14
621	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. Modern Pathology, 2019, 32, 1544-1550.	2.9	45
622	Molecular updates in adipocytic neoplasmsâœ°. Seminars in Diagnostic Pathology, 2019, 36, 85-94.	1.0	22
623	MicroRNAs, Hypoxia and the Stem-Like State as Contributors to Cancer Aggressiveness. Frontiers in Genetics, 2019, 10, 125.	1.1	42
624	Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. Journal of Neuro-Oncology, 2019, 142, 435-444.	1.4	14
625	The Genetic Landscape of Human Glioblastoma and Matched Primary Cancer Stem Cells Reveals Intratumour Similarity and Intertumour Heterogeneity. Stem Cells International, 2019, 2019, 1-12.	1.2	29
626	TERT promoter mutation as a diagnostic marker for diffuse gliomas. Neuro-Oncology, 2019, 21, 417-418.	0.6	6
627	Telomerase reverse transcriptase alterations in human cancers: Diagnosis, prognosis, and therapeutic implications. Cancer Cytopathology, 2019, 127, 275-277.	1.4	0
628	Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagnostic Pathology, 2019, 14, 29.	0.9	40
629	Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas. Neuro-Oncology, 2019, 21, 1005-1015.	0.6	15
630	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	3.2	26
631	Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma. Diagnostic and Interventional Imaging, 2019, 100, 411-419.	1.8	20
632	Profiling of LINE-1-Related Genes in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 645.	1.8	5
633	High-grade Adenocarcinoma of the Prostate Mimicking Urothelial Carcinoma is Negative for TERT Mutations. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 523-528.	0.6	2
634	Stereotactic radiosurgery in the management of oligodendroglioma. , 2019, , 271-278.		1
636	Telomere Maintenance in Pediatric Cancer. International Journal of Molecular Sciences, 2019, 20, 5836.	1.8	10
637	Brain Tumors of Glial Origin. Advances in Experimental Medicine and Biology, 2019, 1190, 281-297.	0.8	19

#	Article	IF	Citations
638	Genomic Landscape of Intramedullary Spinal Cord Gliomas. Scientific Reports, 2019, 9, 18722.	1.6	28
639	Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. Frontiers in Genetics, 2019, 10, 1237.	1.1	43
640	Granular cell astrocytoma: an aggressive <scp>IDH</scp>â€wildtype diffuse glioma with molecular genetic features of primary glioblastoma. Brain Pathology, 2019, 29, 193-204.	2.1	7
641	Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling. Human Pathology, 2019, 86, 170-181.	1.1	24
642	Pathogenic TERT promoter variants in telomere diseases. Genetics in Medicine, 2019, 21, 1594-1602.	1.1	37
643	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenaseâ€“mutant Glioma. Clinical Cancer Research, 2019, 25, 1261-1271.	3.2	50
644	Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Human Pathology, 2019, 85, 1-9.	1.1	28
645	Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis. Journal of Neuro-Oncology, 2019, 141, 289-301.	1.4	11
646	The Identification and Interpretation of cis-Regulatory Noncoding Mutations in Cancer. High-Throughput, 2019, 8, 1.	4.4	7
647	TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, 80, 660-669.e6.	0.6	27
648	Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. Neurotherapeutics, 2019, 16, 319-347.	2.1	32
649	MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma. Journal of Neuroimaging, 2019, 29, 357-363.	1.0	23
650	Sensitive and rapid detection ofTERTpromoter andIDHmutations in diffuse gliomas. Neuro-Oncology, 2019, 21, 440-450.	0.6	27
651	The role of telomere shortening in carcinogenesis: A hybrid stochastic-deterministic approach. Journal of Theoretical Biology, 2019, 460, 144-152.	0.8	7
652	The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis. Journal of Neuro-Oncology, 2019, 142, 1-10.	1.4	31
653	The molecular landscape of glioma in patients with Neurofibromatosis 1. Nature Medicine, 2019, 25, 176-187.	15.2	145
654	Non-duplex G-Quadruplex Structures Emerge as Mediators of Epigenetic Modifications. Trends in Genetics, 2019, 35, 129-144.	2.9	77
655	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	1.6	30

#	Article	IF	Citations
656	Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 77.e17-77.e25.	0.8	12
657	Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediateâ€cell carcinoma?. Histopathology, 2020, 76, 265-274.	1.6	18
658	Practical Molecular Testing in a Clinical Genitourinary Service. Archives of Pathology and Laboratory Medicine, 2020, 144, 277-289.	1.2	5
659	Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases. Brain Pathology, 2020, 30, 235-245.	2.1	12
660	Viral vector: potential therapeutic for glioblastoma multiforme. Cancer Gene Therapy, 2020, 27, 270-279.	2.2	23
661	Histological and molecular features of solitary fibrous tumor of the extremities: clinical correlation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 445-454.	1.4	17
662	Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 423-429.	1.4	30
663	Role of Heredity in Melanoma Susceptibility. Surgical Clinics of North America, 2020, 100, 13-28.	0.5	14
664	Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population. Genomics, 2020, 112, 1746-1753.	1.3	10
665	Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage. Brain Tumor Pathology, 2020, 37, 5-13.	1.1	15
666	Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis. Endocrine, 2020, 67, 44-57.	1.1	52
667	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. Modern Pathology, 2020, 33, 1165-1171.	2.9	18
668	Is There an Independent Role of TERT and NF1 in High Grade Gliomas?. Translational Oncology, 2020, 13, 346-354.	1.7	11
669	Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center. Journal of Cancer, 2020, 11, 1371-1382.	1.2	12
670	The transcription factor FLI1 promotes cancer progression by affecting cell cycle regulation. International Journal of Cancer, 2020, 147, 189-201.	2.3	16
671	Altered cellular metabolism in gliomas â€" an emerging landscape of actionable co-dependency targets. Nature Reviews Cancer, 2020, 20, 57-70.	12.8	187
672	Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System. Advances in Anatomic Pathology, 2020, 27, 206-219.	2.4	7
673	New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Annals of Oncology, 2020, 31, 1679-1692.	0.6	32

#	Article	IF	Citations
674	Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro. Experimental Cell Research, 2020, 396, 112298.	1.2	10
675	Telomere Maintenance Associated Mutations in the Genetic Landscape of Gynecological Mucosal Melanoma. Frontiers in Oncology, 2020, 10, 1707.	1.3	5
676	The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma. Cancers, 2020, 12, 2973.	1.7	39
677	Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. Molecules, 2020, 25, 4641.	1.7	7
678	NIMBus: a negative binomial regression based Integrative Method for mutation Burden Analysis. BMC Bioinformatics, 2020, 21, 474.	1.2	1
679	Current clinical management of elderly patients with glioma. Expert Review of Anticancer Therapy, 2020, 20, 1037-1048.	1.1	8
680	Crossroads of telomere biology and anticancer drug discovery. Cancer Science, 2020, 111, 3089-3099.	1.7	28
681	The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. Cancers, 2020, 12, 1831.	1.7	29
682	Getting under the skin: The role of CDK4/6 in melanomas. European Journal of Medicinal Chemistry, 2020, 204, 112531.	2.6	19
683	Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. BMC Urology, 2020, 20, 99.	0.6	6
684	Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential. Cancers, 2020, 12, 1901.	1.7	34
685	The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 2020, 150, 143-164.	1.4	9
686	To Become or Not to Become Tumorigenic: Subventricular Zone Versus Hippocampal Neural Stem Cells. Frontiers in Oncology, 2020, 10, 602217.	1.3	10
687	Whole-Genome-Sequenzierung von Schleimhautmelanomen zeigt diverse Treiber und therapeutische Targets auf. Karger Kompass Onkologie, 2020, 7, 119-135.	0.0	0
688	TERTâ€"Regulation and Roles in Cancer Formation. Frontiers in Immunology, 2020, 11, 589929.	2.2	121
689	Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. Frontiers in Cell and Developmental Biology, 2020, 8, 580464.	1.8	8
690	Emerging Contribution of PancRNAs in Cancer. Cancers, 2020, 12, 2035.	1.7	3
691	Telomeres and Telomerase in the Development of Liver Cancer. Cancers, 2020, 12, 2048.	1.7	30

#	Article	IF	Citations
692	Genomics and the Immune Landscape of Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1258, 21-36.	0.8	31
693	Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR. Brain Tumor Pathology, 2020, 37, 154-158.	1.1	7
694	TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends. Cancer Letters, 2020, 493, 1-9.	3.2	30
695	Glioblastoma-Derived Extracellular Vesicles Facilitate Transformation of Astrocytes via Reprogramming Oncogenic Metabolism. IScience, 2020, 23, 101420.	1.9	30
696	TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients. Frontiers in Oncology, 2020, 10, 1275.	1.3	18
697	Targeting telomerase for cancer therapy. Oncogene, 2020, 39, 5811-5824.	2.6	122
698	The Development and Application of a Base Editor in Biomedicine. BioMed Research International, 2020, 2020, 1-12.	0.9	2
699	Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies KRAS mutation as a biomarker of poor prognosis. Journal of Medical Genetics, 2022, 59, 10-17.	1.5	11
700	The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer, 2020, 20, 897.	1.1	26
701	Illuminating the noncoding genome in cancer. Nature Cancer, 2020, 1, 864-872.	5.7	37
702	A tailored nextâ€generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Cancer Science, 2020, 111, 3902-3911.	1.7	34
703	Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 6034.	1.8	17
704	New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma. Acta Neuropathologica Communications, 2020, 8, 145.	2.4	13
705	Development of Selective DNA-Interacting Ligands. Springer Theses, 2020, , .	0.0	0
706	TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for antiâ€CTLA4 treatment. Cancer Medicine, 2020, 9, 7151-7160.	1.3	33
707	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. Biomedicines, 2020, 8, 294.	1.4	39
708	Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma. Cancers, 2020, 12, 3825.	1.7	33
709	Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma. Neoplasia, 2020, 22, 800-808.	2.3	9

#	Article	IF	Citations
710	Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. Clinical Cancer Research, 2020, 26, 3819-3830.	3.2	23
711	Promoter region mutations of the telomerase reverse transcriptase (TERT) gene in head and neck squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020, 130, 63-70.	0.2	12
712	Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know. Acta Neurochirurgica, 2020, 162, 1929-1939.	0.9	10
713	Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. Cellular Oncology (Dordrecht), 2020, 43, 847-861.	2.1	14
714	Noninvasive Prediction of TERT Promoter Mutations in High-Grade Glioma by Radiomics Analysis Based on Multiparameter MRI. BioMed Research International, 2020, 2020, 1-11.	0.9	33
715	Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients. Cell Cycle, 2020, 19, 1632-1640.	1.3	20
716	IDH-Mutant Gliomas. , 2020, , .		4
717	Lower Grade Gliomas. Current Neurology and Neuroscience Reports, 2020, 20, 21.	2.0	68
718	TERT promoter mutation determines apoptotic and therapeutic responses of BRAF -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15846-15851.	3.3	31
719	Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma. Pathology International, 2020, 70, 624-632.	0.6	12
720	New tools to dissect the cancer genome. Oral Diseases, 2020, 26, 1101-1106.	1.5	0
721	TERT C228T mutation in nonâ€malignant bladder urothelium is associated with intravesical recurrence for patients with nonâ€muscle invasive bladder cancer. Molecular Oncology, 2020, 14, 2375-2383.	2.1	20
722	The Solo Play of TERT Promoter Mutations. Cells, 2020, 9, 749.	1.8	27
723	CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nature Communications, 2020, 11, 1557.	5.8	38
724	Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Brain Tumor Pathology, 2020, 37, 33-40.	1.1	38
725	Regulation of human telomerase in homeostasis and disease. Nature Reviews Molecular Cell Biology, 2020, 21, 384-397.	16.1	193
726	Genomic Subtyping in Bladder Cancer. Current Urology Reports, 2020, 21, 9.	1.0	18
727	TERT promoter mutations and telomeres during tumorigenesis. Current Opinion in Genetics and Development, 2020, 60, 56-62.	1.5	50

#	Article	IF	Citations
728	Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. Cancers, 2020, 12, 653.	1.7	8
729	TERT, a promoter of CNS malignancies. Neuro-Oncology Advances, 2020, 2, vdaa025.	0.4	22
730	Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns. Cancers, 2020, 12, 1625.	1.7	3
731	Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Modern Pathology, 2020, 33, 2580-2590.	2.9	29
732	TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 947.	1.8	19
733	Making heads or tails â€“ the emergence of capicua (CIC) as an important multifunctional tumour suppressor. Journal of Pathology, 2020, 250, 532-540.	2.1	20
734	Loss of 5â€²-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness. Cells, 2020, 9, 492.	1.8	19
735	Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study. EBioMedicine, 2020, 53, 102643.	2.7	51
736	Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nature Cell Biology, 2020, 22, 282-288.	4.6	96
737	TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis. Journal of Neuropathology and Experimental Neurology, 2020, 79, 430-436.	0.9	6
738	Optimising gene editing for cancer therapy. Nature Cell Biology, 2020, 22, 259-261.	4.6	11
739	The hTERT core promoter forms three parallel G-quadruplexes. Nucleic Acids Research, 2020, 48, 5720-5734.	6.5	61
740	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. Journal of Physical Education and Sports Management, 2020, 6, a004713.	0.5	5
741	Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. International Journal of Molecular Sciences, 2020, 21, 685.	1.8	18
742	TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 381-389.	1.2	15
743	Genomic footprints of activated telomere maintenance mechanisms in cancer. Nature Communications, 2020, 11, 733.	5.8	87
744	Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. Modern Pathology, 2020, 33, 1802-1810.	2.9	7
745	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	0.6	543

#	Article	IF	Citations
746	Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers. Molecular Cancer Research, 2020, 18, 1050-1062.	1.5	21
747	Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Research, 2020, 80, 2663-2675.	0.4	55
748	Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas. Cancer Informatics, 2020, 19, 117693512091583.	0.9	7
749	Telomere-related Markers for Cancer. Current Topics in Medicinal Chemistry, 2020, 20, 410-432.	1.0	40
750	A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report. Visceral Medicine, 2021, 37, 116-119.	0.5	0
751	Aberrant Rac pathway signalling in glioblastoma. Small GTPases, 2021, 12, 81-95.	0.7	1
752	Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma. Child's Nervous System, 2021, 37, 809-818.	0.6	22
753	TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas. Clinical Cancer Research, 2021, 27, 169-178.	3.2	50
754	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. Journal of Molecular Diagnostics, 2021, 23, 253-263.	1.2	20
755	SPT6 recruits SND1 to coâ€activate human telomerase reverse transcriptase to promote colon cancer progression. Molecular Oncology, 2021, 15, 1180-1202.	2.1	7
756	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	3.2	194
757	Glioblastoma and malignant melanoma: Serendipitous or anticipated association?. Neuropathology, 2021, 41, 65-71.	0.7	4
758	Biology of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 29-56.	0.9	40
759	Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. Oncologist, 2021, 26, 173-177.	1.9	23
760	Negative Prognostic Implication of TERT Promoter Mutations in Human Papillomavirusâ€“Negative Tonsillar Squamous Cell Carcinoma Under the New 8th AJCC Staging System. Indian Journal of Surgical Oncology, 2021, 12, 134-143.	0.3	5
761	Is it a new culprit? â€œTERT promoter mutationâ€•in an aggressive pediatric pilocytic astrocytoma. Child's Nervous System, 2021, 37, 1003-1008.	0.6	0
762	Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1118-1125.	1.4	21
763	Overview of glioblastoma biological hallmarks and molecular pathology. , 2021, , 1-15.		0

#	Article	IF	Citations
764	Approach to the low-grade glioma patient. , 2021, , 136-152.		0
765	Machine learning classifiers for predicting 3-year progression-free survival and overall survival in patients with gliomas after surgery. Journal of Cancer, 2021, 12, 1604-1615.	1.2	1
766	Genomic Heterogeneity of Aggressive Pediatric and Adult Diffuse Astrocytomas. Molecular Pathology Library, 2021, , 153-174.	0.1	0
767	Telomeres: history, health, and hallmarks of aging. Cell, 2021, 184, 306-322.	13.5	248
768	Glioma Survival Analysis Empowered With Data Engineeringâ€"A Survey. IEEE Access, 2021, 9, 43168-43191.	2.6	24
769	Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation. Nature Communications, 2021, 12, 139.	5.8	39
770	Immunohistochemical Surrogates for Molecular Pathology. Molecular Pathology Library, 2021, , 175-195.	0.1	0
771	Molecular Stratification of Adult and Pediatric High Grade Gliomas. Molecular Pathology Library, 2021, , 123-151.	0.1	0
773	TERT Promoter Mutations Correlate with IDHs, MGMT and EGFR in Glioblastoma Multiforme. Neurology India, 2021, 69, 135.	0.2	3
774	The place and prognostic value of tert promoter mutation in molecular classification in grade ii-iii glial tumors and primary glioblastomas. Turk Patoloji Dergisi, 2021, , .	0.1	4
775	Diffuse Glioma Heterogeneity and Its Therapeutic Implications. Cancer Discovery, 2021, 11, 575-590.	7.7	193
776	Recent Developments in Small-Molecule Ligands of Medicinal Relevance for Harnessing the Anticancer Potential of G-Quadruplexes. Molecules, 2021, 26, 841.	1.7	38
777	Human TERT promoter mutations as a prognostic biomarker in glioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1007-1017.	1.2	21
778	Non-canonical roles of canonical telomere binding proteins in cancers. Cellular and Molecular Life Sciences, 2021, 78, 4235-4257.	2.4	21
779	Cancer regulatory variation. Current Opinion in Genetics and Development, 2021, 66, 41-49.	1.5	6
780	A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma. Frontiers in Oncology, 2020, 10, 597486.	1.3	10
781	Solid tumours hijack the histone variant network. Nature Reviews Cancer, 2021, 21, 257-275.	12.8	39
782	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Modern Pathology, 2021, 34, 1245-1260.	2.9	21

#	Article	IF	Citations
783	Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	28
784	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	3.9	32
785	Prognostic value of mutations in isocitrate dehydrogenase 1 (IDH1) and reverse telomerase transcriptase (TERT) in Argentine patients` gliomas. Ars Medica, 2021, 46, 12-19.	0.1	0
786	TERT Promoter Alterations in Glioblastoma: A Systematic Review. Cancers, 2021, 13, 1147.	1.7	31
787	Human TERT promoter polymorphism rs2853669 is associated with cancers: an updated meta-analysis. Human Cell, 2021, 34, 1066-1081.	1.2	7
788	TERT promoter mutation in patients with second primary of tongue squamous cell carcinoma. Oral Oncology, 2021, 114, 105089.	0.8	2
789	Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	13
790	Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas. Journal of Neuroradiology, 2021, 49, 59-59.	0.6	5
791	Targeting Protein Kinase C in Glioblastoma Treatment. Biomedicines, 2021, 9, 381.	1.4	13
792	Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell, 2021, 39, 509-528.e20.	7.7	327
793	Morphologic and Molecular Aspects of Glioblastomas. Neurosurgery Clinics of North America, 2021, 32, 149-158.	0.8	3
795	Telomerase reverse transcriptase promoter mutationâ€“ and O6-methylguanine DNA methyltransferase promoter methylationâ€“mediated sensitivity to temozolomide in isocitrate dehydrogenaseâ€“wild-type glioblastoma: is there a link?. European Journal of Cancer, 2021, 147, 84-94.	1.3	10
796	Targeting glioblastoma: from dream to reality. Biomarkers in Medicine, 2021, 15, 385-388.	0.6	3
797	Glioblastoma Primary Cells Retain the Most Copy Number Alterations That Predict Poor Survival in Glioma Patients. Frontiers in Oncology, 2021, 11, 621432.	1.3	2
798	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer, 2021, 7, 43.	2.3	16
799	Distinct <scp>TERT</scp> promoter <scp>C228T</scp> and <scp>C250T</scp> mutations in a patient with an oligodendroglioma: A case report. Neuropathology, 2021, 41, 236-242.	0.7	2
801	Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification. World Neurosurgery, 2021, 148, e471-e481.	0.7	7
802	Integrated Analysis of Nine Prognostic RNA-Binding Proteins in Soft Tissue Sarcoma. Frontiers in Oncology, 2021, 11, 633024.	1.3	6

#	Article	IF	Citations
803	WEVar: a novel statistical learning framework for predicting noncoding regulatory variants. Briefings in Bioinformatics, 2021, 22, .	3.2	5
804	Human telomerase is directly regulated by non-telomeric TRF2-G-quadruplex interaction. Cell Reports, 2021, 35, 109154.	2.9	16
805	ALT Positivity in Human Cancers: Prevalence and Clinical Insights. Cancers, 2021, 13, 2384.	1.7	40
806	Frontiers in Bladder Cancer Genomic Research. Frontiers in Oncology, 2021, 11, 670729.	1.3	11
808	An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro-Oncology, 2021, 23, 1911-1921.	0.6	4
809	A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study. BMC Surgery, 2021, 21, 238.	0.6	13
810	Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error. Cancer Research and Treatment, 2022, 54, 75-83.	1.3	7
811	Molecular alterations in basal cell carcinoma subtypes. Scientific Reports, 2021, 11, 13206.	1.6	19
812	SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. Modern Pathology, 2021, 34, 1810-1819.	2.9	8
813	Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. Brain Tumor Pathology, 2021, 38, 201-209.	1.1	10
814	Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors. Dermato, 2021, 1, 18-25.	0.6	0
815	Stem cells for the treatment of glioblastoma: a 20-year perspective. CNS Oncology, 2021, 10, CNS73.	1.2	14
816	TERT and its binding protein: overexpression of GABPA/B in high grade gliomas. Oncotarget, 2021, 12, 1271-1280.	0.8	2
817	Genetic and biological hallmarks of colorectal cancer. Genes and Development, 2021, 35, 787-820.	2.7	159
818	Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines. BioMed Research International, 2021, 2021, 1-11.	0.9	2
819	Human MettL3-MettL14 RNA adenine methyltransferase complex is active on double-stranded DNA containing lesions. Nucleic Acids Research, 2021, 49, 11629-11642.	6.5	40
820	18F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors. Cancers, 2021, 13, 3163.	1.7	5
821	Clinical implications of molecular analysis in diffuse glioma stratification. Brain Tumor Pathology, 2021, 38, 210-217.	1.1	6

#	Article	IF	Citations
822	A Brief Overview and Update on Major Molecular Genomic Alterations in Solid, Bone and Soft Tissue Tumors, and Hematopoietic As Well As Lymphoid Malignancies. Archives of Pathology and Laboratory Medicine, 2021, 145, 1358-1366.	1.2	2
823	Coexistence of TERT C228T mutation and MALAT1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets. Neurological Research, 2021, 43, 916-925.	0.6	5
824	Simplified approach for pathological diagnosis of diffuse gliomas in adult patients. Pathology Research and Practice, 2021, 223, 153483.	1.0	6
825	Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer. Scientific Reports, 2021, 11, 15355.	1.6	1
826	Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. Cancers, 2021, 13, 3771.	1.7	7
827	Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma. Frontiers in Oncology, 2021, 11, 705440.	1.3	12
828	Non-coding driver mutations in human cancer. Nature Reviews Cancer, 2021, 21, 500-509.	12.8	59
829	Sensitive Detection of Molecular Targets in Cancer by Minisequencing. Acibadem Universitesi Saglik Bilimleri Dergisi, 2021, 12, .	0.0	0
830	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. Frontiers in Immunology, 2021, 12, 682492.	2.2	18
831	Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review). Oncology Reports, 2021, 46, .	1.2	10
832	Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. Journal of Antibiotics, 2021, 74, 617-628.	1.0	10
833	How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?. Biomolecules, 2021, 11, 1112.	1.8	7
834	TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology, 2021, 5, 1259-1269.	1.5	10
835	Occurrence, functionality and abundance of the <scp>TERT</scp> promoter mutations. International Journal of Cancer, 2021, 149, 1852-1862.	2.3	13
836	Exploring the Interplay of Telomerase Reverse Transcriptase and Î²-Catenin in Hepatocellular Carcinoma. Cancers, 2021, 13, 4202.	1.7	9
837	Significance of cytoplasmic expression of telomerase reverse transcriptase in patients with hepatocellular carcinoma undergoing liver resection. Molecular and Clinical Oncology, 2021, 15, 244.	0.4	2
838	Telomeres and Age-Related Diseases. Biomedicines, 2021, 9, 1335.	1.4	37
839	A Modified Nucleoside 6-Thio-2â€²-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	3.2	10

#	Article	IF	Citations
840	An Overview of the Genomic Characterization of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1077-1088.	1.8	8
841	Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines. ELife, 2021, 10, .	2.8	8
842	Human TERT Promoter Mutations in Atypical and Anaplastic Meningiomas. Diagnostics, 2021, 11, 1624.	1.3	3
843	The Evolving Molecular Landscape of High-Grade Gliomas. Cancer Journal (Sudbury, Mass), 2021, 27, 337-343.	1.0	5
844	Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4415-4425.	3.3	29
845	Mutations in Noncoding Cis-Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer. Molecular Cancer Research, 2022, 20, 102-113.	1.5	3
846	Telomerase as a therapeutic target in glioblastoma. Neuro-Oncology, 2021, 23, 2004-2013.	0.6	17
847	Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. Laboratory Investigation, 2022, 102, 126-133.	1.7	69
848	Targeting the genetic landscape of oral potentially malignant disorders has the potential as a preventative strategy in oral cancer. Cancer Letters, 2021, 518, 102-114.	3.2	14
849	Genetic Architectures and Cell-of-Origin in Glioblastoma. Frontiers in Oncology, 2020, 10, 615400.	1.3	26
850	Pathology, Molecular Biology and Classification of Gliomas. , 2021, , 37-55.		0
851	TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers. Neurology India, 2021, 69, 126.	0.2	2
852	The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells. Frontiers in Oncology, 2020, 10, 603738.	1.3	7
853	Advances in Research of Adult Gliomas. International Journal of Molecular Sciences, 2021, 22, 924.	1.8	27
854	Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and 1p/19q codeleted oligodendroglioma. Neuro-Oncology Advances, 2021, 3, vdab081.	0.4	1
856	Molecular Pathology and Genomics of Melanoma. , 2020, , 381-422.		1
857	Molecular Pathology and Genomics of Melanoma. , 2019, , 1-42.		2
858	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. , 2017, , 73-100.		2

#	Article	IF	Citations
859	Reconstruction of enhancerâ€“target networks in 935 samples of human primary cells, tissues and cell lines. Nature Genetics, 2017, 49, 1428-1436.	9.4	194
860	Adult precision medicine: learning from the past to enhance the future. Neuro-Oncology Advances, 2021, 3, vdaa145.	0.4	11
867	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. Journal of Clinical Investigation, 2020, 130, 3005-3020.	3.9	12
868	TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma. PLoS ONE, 2013, 8, e80354.	1.1	78
869	TERT Promoter Mutations Lead to High Transcriptional Activity under Hypoxia and Temozolomide Treatment and Predict Poor Prognosis in Gliomas. PLoS ONE, 2014, 9, e100297.	1.1	36
870	Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e107276.	1.1	20
871	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2016, 11, e0149756.	1.1	66
872	BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PLoS ONE, 2016, 11, e0153319.	1.1	55
873	Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer. PLoS ONE, 2017, 12, e0174032.	1.1	9
874	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	1.1	27
875	SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. PLoS ONE, 2017, 12, e0180392.	1.1	2
876	Not the same thing: metastatic PTCs have a different background than ATCs. Endocrine Connections, 2018, 7, 1370-1379.	0.8	14
877	The genetics of cutaneous squamous cell carcinogenesis. European Journal of Dermatology, 2018, 28, 597-605.	0.3	8
879	Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas. Aging, 2019, 11, 6252-6272.	1.4	32
880	Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma. Aging, 2020, 12, 17288-17294.	1.4	7
881	Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma. Oncotarget, 2016, 7, 69267-69275.	0.8	33
882	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	0.8	21
883	Association between rs2853669 in TERT gene and the risk and prognosis of human cancer: a systematic review and meta-analysis. Oncotarget, 2017, 8, 50864-50872.	0.8	24

#	Article	IF	Citations
884	Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma. Oncotarget, 2017, 8, 26288-26297.	0.8	9
885	Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget, 2017, 8, 35523-35531.	0.8	8
886	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget, 2014, 5, 1515-1525.	0.8	237
887	TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget, 2014, 5, 1829-1836.	0.8	57
888	ATRXmRNA expression combined withIDH1/2mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples. Oncotarget, 2014, 5, 2551-2561.	0.8	61
889	Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status. Oncotarget, 2017, 8, 57134-57148.	0.8	17
890	Expression level ofhTERTis regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget, 2014, 5, 3399-3407.	0.8	50
891	Sensitive droplet digital PCR method for detection ofTERTpromoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 2017, 8, 78890-78900.	0.8	44
892	TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer. Oncotarget, 2017, 8, 77540-77551.	0.8	34
893	Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	0.8	89
894	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget, 2014, 5, 7960-7979.	0.8	35
895	TERT promoter mutations and gene amplification: Promoting TERT expression in Merkel cell carcinoma. Oncotarget, 2014, 5, 10048-10057.	0.8	49
896	TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Oncotarget, 2014, 5, 12428-12439.	0.8	58
897	TERT promoter mutations in melanoma survival. Oncotarget, 2019, 10, 1546-1548.	0.8	27
898	Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. Oncotarget, 2019, 10, 3641-3653.	0.8	1
899	In silico identification and functional validation of allele-dependent AR enhancers. Oncotarget, 2015, 6, 4816-4828.	0.8	6
900	TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget, 2015, 6, 10617-10633.	0.8	79
901	The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer. Oncotarget, 2015, 6, 19542-19551.	0.8	43

#	Article	IF	Citations
902	TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget, 2015, 6, 16663-16673.	0.8	100
903	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget, 2015, 6, 30295-30305.	0.8	113
904	TERTpromoter mutations contribute toIDHmutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Oncotarget, 2015, 6, 24871-24883.	0.8	34
905	Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis. Oncotarget, 2015, 6, 25109-25120.	0.8	46
906	Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget, 2016, 7, 5030-5041.	0.8	45
907	Frequent DPH3 promoter mutations in skin cancers. Oncotarget, 2015, 6, 35922-35930.	0.8	60
908	Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget, 2015, 6, 43452-43471.	0.8	62
909	Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget, 2015, 6, 42468-42477.	0.8	87
910	The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients. Oncotarget, 2016, 7, 25826-25835.	0.8	16
911	Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget, 2016, 7, 27838-27847.	0.8	25
912	Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget, 2016, 7, 54253-54262.	0.8	50
913	Malignant Intracranial High Grade Glioma and Current Treatment Strategy. Current Cancer Drug Targets, 2019, 19, 101-108.	0.8	13
914	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Current Topics in Medicinal Chemistry, 2020, 20, 433-457.	1.0	33
915	Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group. Neurologia Medico-Chirurgica, 2020, 60, 543-552.	1.0	4
916	The mutational landscape of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2015, 21, 220.	4.5	108
917	Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World Journal of Gastroenterology, 2014, 20, 12945.	1.4	117
918	Association between functional TERT promoter polymorphism rs2853669 and cervical cancer risk in South Indian women. Molecular and Clinical Oncology, 2020, 12, 485-494.	0.4	8
919	Frequency of somatic mutations in promoter, and genes in patients with hepatocellular carcinoma from Southern Italy. Oncology Letters, 2020, 19, 2368-2374.	0.8	16

#	Article	IF	Citations
920	Telomeres and telomerase in oncogenesis (Review). Oncology Letters, 2020, 20, 1015-1027.	0.8	59
921	Current trends in the surgical management and treatment of adult glioblastoma. Annals of Translational Medicine, 2015, 3, 121.	0.7	163
922	A contemporary molecular view of diffuse gliomas with implications for diagnosis. Glioma (Mumbai,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	1
923	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1537-1570.	2.3	253
924	Taking the brakes off telomerase. ELife, 2015, 4, .	2.8	3
925	Significance of telomerase reverse-transcriptase promoter mutations in differentiated thyroid cancer. Formosan Journal of Surgery, 2021, 54, 171.	0.1	3
926	Glioma: molecular signature and crossroads with tumor microenvironment. Cancer and Metastasis Reviews, 2022, 41, 53-75.	2.7	63
927	Human Telomerase Reverse Transcriptase as a Therapeutic Target of Dihydroartemisinin for Esophageal Squamous Cancer. Frontiers in Pharmacology, 2021, 12, 769787.	1.6	2
928	Glioblastoma and malignant melanoma: Serendipitous or anticipated association?. Neuropathology, 2021, 41, 489-491.	0.7	2
929	Oligodendroglioma: A Review of Management and Pathways. Frontiers in Molecular Neuroscience, 2021, 14, 722396.	1.4	11
930	Genetic Basis for the Development of Adult Gliomas. Japanese Journal of Neurosurgery, 2014, 23, 532-540.	0.0	2
931	The Potential Clinical Implications of Telomerase Reverse Transcriptase in the Detection and Diagnosis of Bladder Cancer. Hereditary Genetics: Current Research, 2014, 03, .	0.1	0
932	Refined Glioma Classification based on Molecular Pathology. Japanese Journal of Neurosurgery, 2015, 24, 366-377.	0.0	0
934	An Overview of the History of Brain Tumor Classification and Glioma Diagnosis in WHO2016. Japanese Journal of Neurosurgery, 2016, 25, 542-547.	0.0	0
935	Radiosensitizing Glioma by Targeting ATM with Small Molecule Inhibitors. , 2016, , 289-305.		0
936	Translating Molecular Biomarkers of Gliomas to Clinical Practice. , 2016, , 33-53.		0
937	TERT rs2853676 polymorphisms correlate with glioma prognosis in Chinese population. Oncotarget, 2016, 7, 73781-73791.	0.8	3
938	Title is missing!. , 2017, , .		0

#	Article	IF	Citations
940	Molecular Carcinogenesis of Glial Brain Tumors. , 2017, , 115-136.		0
941	Molecular Genetics of Thyroid Cancer. , 2017, , 15-27.		0
946	Telomeres and Telomerase: Molecular Views and Perspectives. Advances in Aging Research, 2018, 07, 91-111.	0.3	1
950	Quantitative Proteomics Reveals Global Reduction of Endocytic Machinery Components in Gliomas. SSRN Electronic Journal, 0, , .	0.4	0
953	Genome Medicine for Brain Tumors: Current Status and Future Perspectives. Neurologia Medico-Chirurgica, 2020, 60, 531-542.	1.0	5
955	Immunohistochemical expression of ATRX in gliomas. Cellular and Molecular Biology, 2020, 66, 131.	0.3	1
956	Mouse Models of Diffuse Lower-Grade Gliomas of the Adult. Neuromethods, 2021, , 3-38.	0.2	0
958	Conservation and divergence in gene regulation between mouse and human immune cells deserves equal emphasis. Trends in Immunology, 2021, 42, 1077-1087.	2.9	3
959	Carbonic anhydrase IX as a marker of hypoxia in gliomas: A narrative review. Glioma (Mumbai, India), 2020, 3, 97.	0.0	1
960	Co-Occurrence of Hotspot Point Mutation and Novel Deletion Mutation of TERT Promoter in Solid Variant Papillary Thyroid Carcinoma in a Patient with Synchronous Esophageal Cancer. Diagnostics, 2021, 11, 4.	1.3	5
962	Diagnostic and prognostic implications of molecular status in Chinese adults with diffuse glioma: An observational study. Glioma (Mumbai, India), 2020, 3, 168.	0.0	0
963	Mechanisms of telomere maintenance in pediatric brain tumors: Promising targets for therapy â€“ A narrative review. Glioma (Mumbai, India), 2020, 3, 105.	0.0	1
966	Mechanisms of cell competition in glioblastoma: A narrative review. Glioma (Mumbai, India), 2020, 3, 154.	0.0	1
969	Telomerase inhibition decreases esophageal squamous carcinoma cell migration and invasion. Oncology Letters, 2020, 20, 2870-2880.	0.8	3
972	VHA Practice Guideline Recommendations for Diffuse Gliomas. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2018, 35, S28-S35.	0.6	1
974	Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas. International Journal of Clinical and Experimental Pathology, 2020, 13, 230-238.	0.5	5
975	Clinicopathologic features and prognosis of epithelioid glioblastoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 1529-1539.	0.5	1
976	A review of gliomas-related proteins. Characteristics of potential biomarkers. American Journal of Cancer Research, 2021, 11, 3425-3444.	1.4	1

#	Article	IF	Citations
977	Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma. Cancer Science, 2021, 113, 697.	1.7	4
978	Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas. Cancers, 2021, 13, 5678.	1.7	6
979	Nonâ€coding regulatory elements: Potential roles in disease and the case of epilepsy. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	14
980	TERT Promoter Mutations Increase Sense and Antisense Transcription from the TERT Promoter. Biomedicines, 2021, 9, 1773.	1.4	6
981	Comprehensive omics analyses profile genesets related with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype. Theranostics, 2022, 12, 459-473.	4.6	5
982	Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study. Radiotherapy and Oncology, 2022, 167, 1-6.	0.3	3
983	TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis. Biology, 2022, 11, 141.	1.3	3
984	Genome-wide screens identify specific drivers of mutant hTERT promoters. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
985	Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements. Clinical Cancer Research, 2022, 28, 1724-1733.	3.2	8
986	A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them. Frontiers in Genetics, 2021, 12, 832627.	1.1	0
987	High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis. Cancer Science, 2022, 113, 1078-1089.	1.7	10
988	Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma. Scientific Reports, 2022, 12, 546.	1.6	7
989	Multiple ETS Factors Participate in the Transcriptional Control of TERT Mutant Promoter in Thyroid Cancers. Cancers, 2022, 14, 357.	1.7	11
990	Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. Brain Tumor Pathology, 2022, 39, 121-129.	1.1	7
991	A promising glycolysis and immune related prognostic signature for glioblastoma (GBM). World Neurosurgery, 2022, , .	0.7	4
992	Unique case of IgG4-related disease of the renal pelvis involving the inferior vena cava masquerading as locally advanced urothelial cancer. BMJ Case Reports, 2022, 15, e247945.	0.2	0
993	Glioma targeted therapy: insight into future of molecular approaches. Molecular Cancer, 2022, 21, 39.	7.9	274
995	Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers. BMC Medical Genomics, 2022, 15, 25.	0.7	3

#	Article	IF	Citations
996	Telomerase in hepatocellular carcinoma. , 2022, , 181-197.		0
997	Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma. Biomedicines, 2022, 10, 564.	1.4	24
998	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of Pathology and Laboratory Medicine, 2022, 146, 547-574.	1.2	25
1000	Surgical Neuro-Oncology. Neurologic Clinics, 2022, 40, 437-453.	0.8	6
1001	TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo. Neuro-Oncology, 2022, 24, 2063-2075.	0.6	9
1002	Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients. International Journal of Cancer, 2022, 150, 1879-1888.	2.3	5
1003	Detection of TERT Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances. Biomedicines, 2022, 10, 728.	1.4	16
1004	The Subventricular Zone in Glioblastoma: Genesis, Maintenance, and Modeling. Frontiers in Oncology, 2022, 12, 790976.	1.3	11
1005	Classification of adultâ€type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathology, 2022, 32, e13062.	2.1	53
1006	Oral Senescence: From Molecular Biology to Clinical Research. Frontiers in Dental Medicine, 2022, 3, .	0.5	3
1007	Prospective genomically guided identification of â€œearly/evolvingâ€•and â€œundersampledâ€•IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	0.6	10
1008	Inhibiting the growth of melanoma cells via hTERT gene editing using CRISPR-dCas9-dnmt3a system. Gene, 2022, 828, 146477.	1.0	3
1009	Clinicopathological indicators for TERT promoter mutation in papillary thyroid carcinoma. Clinical Endocrinology, 2022, 97, 106-115.	1.2	7
1011	Unravelling undifferentiated soft tissue sarcomas: insights from genomics. Histopathology, 2022, 80, 109-121.	1.6	3
1012	Telomeres and Cancer. Life, 2021, 11, 1405.	1.1	11
1013	Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines. In Vivo, 2022, 36, 94-102.	0.6	3
1014	Long-term outcome and surrogate molecular signatures of pediatric patients with diffuse astrocytomas. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 69-77.	0.1	1
1015	Analysis of the Cancer Genome Atlas Data to Determine the Prognostic Value of GABPB1L and TERT in Glioblastoma. Keimyung Medical Journal, 2021, 40, 73-76.	0.1	1

#	Article	IF	Citations
1017	A Qualitative Signature to Identify TERT Promoter Mutant High-Risk Tumors in Low-Grade Gliomas. Frontiers in Molecular Biosciences, 2022, 9, 806727.	1.6	1
1018	Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics. Cancer Imaging, 2022, 22, 19.	1.2	9
1019	Telomerase gene therapy: a remission toward cancer. , 2022, 39, 105.		17
1020	Genome editing: An essential technology for cancer treatment. Medicine in Omics, 2022, , 100015.	0.6	3
1033	Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma. Neuro-Oncology, 2022, , .	0.6	3
1035	Glioblastoma multiforme of spinal cord - Case series in a tertiary cancer centre.. Journal of Clinical and Translational Research, 2021, 7, 792-796.	0.3	1
1036	TERT expression increases with tumor grade in a cohort of -mutant gliomas.. American Journal of Translational Research (discontinued), 2022, 14, 295-303.	0.0	0
1037	Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-11.	0.7	4
1038	Oral Tongue Spontaneous Tumor Regression after Biopsy: A Case Report and Genomic Profile. Ear, Nose and Throat Journal, 2022, , 014556132211000.	0.4	1
1039	Emerging mechanisms of telomerase reactivation in cancer. Trends in Cancer, 2022, 8, 632-641.	3.8	22
1040	Epidemiology of Glioblastoma Multiformeâ€“Literature Review. Cancers, 2022, 14, 2412.	1.7	141
1041	An Update to Hallmarks of Cancer. Cureus, 2022, , .	0.2	4
1042	What the eyes cannot seeâ€”Limitations of current molecular neuropathological interpretations: A primer. International Journal of Neurooncology, 2021, 4, 46.	0.1	0
1043	A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status and the prognosis of lower-grade gliomas. Clinical Radiology, 2022, 77, e560-e567.	0.5	8
1044	Identification of h-TERT Promoter Mutations in Germline DNA from North Indian Lung Carcinoma Patients. Indian Journal of Clinical Biochemistry, 0, , .	0.9	0
1045	Updates in IDH-Wildtype Glioblastoma. Neurotherapeutics, 2022, 19, 1705-1723.	2.1	26
1046	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. British Journal of Cancer, 2022, 127, 976-987.	2.9	26
1047	Telomere length as a biomarker of aging and diseases. Arhiv Za Farmaciju, 2022, 72, 105-126.	0.2	1

#	Article	IF	Citations
1048	Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Human Pathology, 2023, 133, 56-75.	1.1	12
1049	Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma. Frontiers in Oncology, 0, 12, .	1.3	4
1050	Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors. Cancers, 2022, 14, 3015.	1.7	10
1051	Research Progress on G-Quadruplexes in Human Telomeres and Human Telomerase Reverse Transcriptase (hTERT) Promoter. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-11.	1.9	4
1052	A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.. Pathology Research and Practice, 2022, 236, 153983.	1.0	3
1053	Prognostic value of TERT mutation in adults with primary glioblastomas. Preliminary results. Zhurnal Voprosy Nejrokhirurgii Imeni N N Burdenko, 2022, 86, 33.	0.1	0
1054	Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. Cancers, 2022, 14, 3203.	1.7	23
1055	A Promising Preclinical Model For Tert Promoter Mutation In Glioblastoma. Neuro-Oncology, 0, , .	0.6	0
1056	Molecular landscape of <scp>IDH</scp>â€wild type, <scp>pTERT</scp>â€wild type adult glioblastomas. Brain Pathology, 2022, 32, .	2.1	9
1057	Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma. Cancers, 2022, 14, 3537.	1.7	2
1058	Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases. Advanced Science, 2022, 9, .	5.6	19
1059	Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?. Frontiers in Oncology, 0, 12, .	1.3	2
1060	Basic premises: searching for new targets and strategies in diffuse gliomas. Clinical and Translational Imaging, 0, , .	1.1	2
1061	Clinical and pathological characteristics of familial melanoma with germline <scp>TERT</scp> promoter variants. Pigment Cell and Melanoma Research, 2022, 35, 573-586.	1.5	2
1062	The telomere maintenance mechanism spectrum and its dynamics in gliomas. Genome Medicine, 2022, 14, .	3.6	9
1063	TERT distal promoter GC islands are critical for telomerase and together with DNMT3B silencing may serve as a senescence-inducing agent in gliomas. Journal of Neurogenetics, 2022, 36, 89-97.	0.6	1
1064	Demystifying non-coding GWAS variants: an overview of computational tools and methods. Human Molecular Genetics, 2022, 31, R73-R83.	1.4	9
1065	Comprehensive development and validation of gene signature for predicting survival in patients with glioblastoma. Frontiers in Genetics, 0, 13, .	1.1	6

#	Article	IF	Citations
1066	Tieing together loose ends: telomere instability in cancer and aging. Molecular Oncology, 2022, 16, 3380-3396.	2.1	12
1067	Targeted Long-Read Bisulfite Sequencing Identifies Differences in the TERT Promoter Methylation Profiles between TERT Wild-Type and TERT Mutant Cancer Cells. Cancers, 2022, 14, 4018.	1.7	2
1068	Next Steps for Immunotherapy in Glioblastoma. Cancers, 2022, 14, 4023.	1.7	9
1069	Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status. BMC Medical Imaging, 2022, 22, .	1.4	8
1070	G-Quadruplex Formed by the Promoter Region of the hTERT Gene: Structure-Driven Effects on DNA Mismatch Repair Functions. Biomedicines, 2022, 10, 1871.	1.4	8
1071	Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer. Nature Communications, 2022, 13, .	5.8	7
1072	Differential DNA Methylation of THOR and hTAPAS in the Regulation of hTERT and the Diagnosis of Cancer. Cancers, 2022, 14, 4384.	1.7	2
1073	A Versatile System for Comparing Methods for Determining Mutations in the TERT Gene Promoter as an Example of the Analysis of Tumor Lesions of the Central Nervous System. Moscow University Chemistry Bulletin, 2022, 77, 249-255.	0.2	0
1075	GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. Cell Reports, 2022, 40, 111344.	2.9	9
1076	Current therapeutic options for glioblastoma and future perspectives. Expert Opinion on Pharmacotherapy, 2022, 23, 1629-1640.	0.9	5
1077	Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer. Scientific Reports, 2022, 12, .	1.6	2
1078	A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation. Science, 2022, 378, 68-78.	6.0	20
1079	Role of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma. Zhurnal Voprosy Nejrokhirurgii Imeni N N Burdenko, 2022, 86, 21.	0.1	0
1080	Next-Generation Sequencing Comparative Analysis of DNA Mutations between Blood-Derived Extracellular Vesicles and Matched Cancer Tissue in Patients with Grade 4 Glioblastoma. Biomedicines, 2022, 10, 2590.	1.4	0
1081	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro-Oncology, 2023, 25, 4-25.	0.6	45
1082	Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial. Frontiers in Oncology, 0, 12, .	1.3	1
1083	The Role of Telomerase in Breast Cancerâ€™s Response to Therapy. International Journal of Molecular Sciences, 2022, 23, 12844.	1.8	6
1084	Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas. Molecular Cell, 2022, 82, 3919-3931.e7.	4.5	3

#	Article	IF	Citations
1085	Perfiles mutacionales de carcinoma escamoso de pene en cuatro pacientes paraguayos. , 2022, 27, .		1
1086	Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China. BMC Medical Genomics, 2022, 15, .	0.7	6
1087	Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data. Expert Opinion on Therapeutic Targets, 2022, 26, 767-780.	1.5	1
1088	Telomeres expand sphere of influence: emerging molecular impact of telomeres in non-telomeric functions. Trends in Genetics, 2023, 39, 59-73.	2.9	5
1089	Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers. Expert Review of Molecular Diagnostics, 2022, 22, 997-1008.	1.5	4
1090	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). Oncology Letters, 2022, 25, .	0.8	7
1091	Importancia pronÃ³stica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado. Biomedica, 2022, 42, 574-590.	0.3	0
1092	Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. Cancer Biomarkers, 2023, 36, 117-131.	0.8	3
1093	THOR is a targetable epigenetic biomarker with clinical implications in breast cancer. Clinical Epigenetics, 2022, 14, .	1.8	6
1094	TERT genetic polymorphism rs2736100 is associated with an aggressive manifestation of papillary thyroid carcinoma. Frontiers in Surgery, 0, 9, .	0.6	1
1097	Melanoma and Glioblastomaâ€"Not a Serendipitous Association. Advances in Anatomic Pathology, 0, Publish Ahead of Print, .	2.4	0
1098	NCCN GuidelinesÂ® Insights: Central Nervous System Cancers, Version 2.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 12-20.	2.3	44
1099	Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. Advances in Experimental Medicine and Biology, 2023, , 73-84.	0.8	3
1103	Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells. Neuro-Oncology, 2023, 25, 1563-1575.	0.6	5
1104	Forecasting Molecular Features in IDH-Wildtype Gliomas: The State of the Art of Radiomics Applied to Neurosurgery. Cancers, 2023, 15, 940.	1.7	3
1105	The TERT Promoter: A Key Player in the Fight for Cancer Cell Immortality. Biochemistry (Moscow), 2023, 88, S21-S38.	0.7	0
1106	The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer. Cancers, 2023, 15, 2228.	1.7	6
1107	Links between telomere dysfunction and hallmarks of aging. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2023, 888, 503617.	0.9	1

#	Article	IF	Citations
1108	Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder. Modern Pathology, 2023, 36, 100151.	2.9	1
1110	Telomerase inhibition is an effective therapeutic strategy inTERTpromoter-mutant glioblastoma models with low tumor volume. Neuro-Oncology, 2023, 25, 1275-1285.	0.6	8
1111	A Brief Overview of Telomeres and Telomerase in Aging and Cancer. , 2022, 23, .		0
1112	Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6303-6313.	1.2	3
1113	Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of GPR126 Non-Coding Mutations in Bladder Cancer Urine Liquid Biopsies. Biomedicines, 2023, 11, 495.	1.4	1
1114	Transcriptional analysis links B cells and TERT expression to favorable prognosis in head and neck cancer. , 2023, 2, .		2
1115	Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications. Cancers, 2023, 15, 1268.	1.7	2
1116	DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. Cancers, 2023, 15, 1342.	1.7	13
1117	A non-genetic switch triggers alternative telomere lengthening and cellular immortalization in ATRX deficient cells. Nature Communications, 2023, 14, .	5.8	4
1118	Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer. Biomedicines, 2023, 11, 691.	1.4	2
1119	Cross-talk between NF-Î°B and telomerase in cancer: Implications in therapy. , 2023, , 75-82.		0
1120	Transcriptional Regulation during Aberrant Activation of NF-Î°B Signalling in Cancer. Cells, 2023, 12, 788.	1.8	11
1121	Deep Learning Prediction of TERT Promoter Mutation Status in Thyroid Cancer Using Histologic Images. Medicina (Lithuania), 2023, 59, 536.	0.8	2
1122	Telomere Length Changes in Cancer: Insights on Carcinogenesis and Potential for Non-Invasive Diagnostic Strategies. Genes, 2023, 14, 715.	1.0	9
1124	Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives. Biomarker Research, 2023, 11, .	2.8	7
1125	Neural Stem Cells as Potential Glioblastoma Cells of Origin. Life, 2023, 13, 905.	1.1	10
1126	Telomerase. , 2023, , 1-26.		0
1127	Thirty years of progress in the management of low-grade gliomas. Revue Neurologique, 2023, 179, 425-429.	0.6	2

#	Article	IF	Citations
1128	TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance. Oral Oncology, 2023, 140, 106398.	0.8	4
1149	Pathogenesis of cancers derived from thyroid follicular cells. Nature Reviews Cancer, 2023, 23, 631-650.	12.8	6
1151	Malignant Glioma. Advances in Experimental Medicine and Biology, 2023, , 1-30.	0.8	8
1152	Cellular senescence in glioma. Journal of Neuro-Oncology, 2023, 164, 11-29.	1.4	4
1157	Telomerase. , 2023, , 1291-1316.		0
1166	Liquid biopsy: creating opportunities in brain space. British Journal of Cancer, 2023, 129, 1727-1746.	2.9	1
1189	Olovnikov, Telomeres, and Telomerase. Is It Possible to Prolong a Healthy Life?. Biochemistry (Moscow), 2023, 88, 1704-1718.	0.7	0
1196	Genetics of neuronal and glioneuronal cancers. , 2024, , 339-369.		0
1197	Epigenetic dysregulation in brain tumors. , 2024, , 269-285.		0